Neuro-Ophthalmologic Manifestations of Neurodegenerative Disease in Childhood

  • Michael C. Brodsky


Neurodegenerative disorders in children pose a unique diagnostic challenge. Unlike many genetic syndromes, the clinical manifestations of childhood neurodegenerative diseases are often nonspecific and show considerable overlap. Pathognomonic clinical signs are rare. Many of these conditions are uncommon, and extensive clinical experience is generally lacking, even in tertiary referral centers. To further complicate matters, these children often present in the early stages of their illness, when evidence of progression is questionable and motor or cognitive impairment is relatively mild. It is only with extended observation that both clinical and neuroimaging abnormalities evolve to suggest a limited set of diagnostic possibilities. These children usually require repeated observation by a multidisciplinary team of neurologists, neuroimaging specialists, neuro-ophthalmologists, and geneticists before a specific diagnosis is established [266]


Enzyme Replacement Therapy Gauche Disease Visual Evoke Potential Optic Atrophy Metachromatic Leukodystrophy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Abdelhalim AN, Alberico RA, Barczykowski MS, Duffner PK. Patterns of magnetic resonance imaging abnormalities in symptomatic patients with Krabbe disease correspond to phenotype. Pediatr Neurol. 2014;50:127–34.PubMedCrossRefGoogle Scholar
  2. 2.
    Abraham FA, Yatziv S, Russell A, et al. Electrophysiological and psychological findings in Hunter syndrome. Arch Ophthalmol. 1974;91:181–6.PubMedCrossRefGoogle Scholar
  3. 3.
    Accardo AP, Pensiero S, Perssutti P. Saccadic analysis for early identification of neurological involvement in Gaucher disease. Ann NY Acad Sci. 2005;1039:503–7.PubMedCrossRefGoogle Scholar
  4. 4.
    Adams HR, Kwan J, Marshall FJ, et al. Neuropsychological symptoms of juvenile-onset batten disease: experience from 2 studies. J Child Neurol. 2007;22:621–7.PubMedPubMedCentralCrossRefGoogle Scholar
  5. 5.
    Agamanolis DP, Patre S. Glycone accumulation in the central nervous system in the cerebral-pararenal syndrome. J Neurol Sci. 1979;41:325–42.PubMedCrossRefGoogle Scholar
  6. 6.
    Agamanolis DP, Robinson HB, Timmons GD. Cerebral-pararenal syndrome. A report of a case with histochemical and ultrastructural observations. J Neuropathol Exp Neurol. 1976;35:226–46.PubMedCrossRefGoogle Scholar
  7. 7.
    Aisen AM, Martel W, Gabrielson TO, et al. Wilson disease of the brain: MR imaging. Radiology. 1985;157:137–41.PubMedCrossRefGoogle Scholar
  8. 8.
    Akaboshi S, Ohno K, Takeshita K. Neuroradiological findings in the carbohydrate-deficient glycoprotein syndromes: an overview. J Inherit Metab Dis. 1993;16:813–20.CrossRefGoogle Scholar
  9. 9.
    Alexander A. Progressive fibrinoid degeneration of fibrillary astrocytes associated with mental retardation in a hydrocephalic infant. Brain. 1949;72:373.PubMedCrossRefGoogle Scholar
  10. 10.
    Altarescu G, Hill S, Wiggs E, et al. The efficacy of enzyme replacement therapy in patients with chronic neuronopathic Gaucher’s disease. J Pediatr. 2001;138:539–47.PubMedCrossRefGoogle Scholar
  11. 11.
    Alves D, Pires MM, Guimarães A, et al. Four cases of late onset metachromatic leukodystrophy in a family: clinical, biochemical, and neuropathological studies. J Neurol Neurosurg Psychiatry. 1986;49:1417–22.PubMedPubMedCentralCrossRefGoogle Scholar
  12. 12.
    Anawis MA. Hunter syndrome (MPS II-B): a report of bilateral vitreous floaters and maculopathy. Ophthalmic Genet. 2006;27:71–2.PubMedCrossRefGoogle Scholar
  13. 13.
    Andréasoson S, Blennow G, Ehinger B, et al. Full-field electroretinograms in patients with the carbohydrate-deficient glycoprotein syndrome. Am J Ophthalmol. 1991;112:83–6.CrossRefGoogle Scholar
  14. 14.
    Arend AO, Leary PM, Rutherford GS. Alexander’s disease: a case report with brain biopsy, ultrasound, CT scan and MRI findings. Clin Neuropathol. 1991;10:122–6.PubMedGoogle Scholar
  15. 15.
    Arnoldi K. Congenital nystagmus masquerading as spasmus nutans. Am Orthopt J. 1996;46:171–80.Google Scholar
  16. 16.
    Arpaia E, Dumbrille-Ross A, Maler T, et al. Identification of an altered splice site in Ashkenazi Tay-Sachs disease. Nature. 1988;333:85–6.PubMedCrossRefGoogle Scholar
  17. 17.
    Ashworth JL, Biswas S, Wraith E, et al. Mucopolysaccharidoses and the eye. Surv Ophthalmol. 2006;51:1–17.PubMedCrossRefGoogle Scholar
  18. 18.
    Aubourg P, Scotto J, Rocchiccioli F, et al. Neonatal adrenoleukodystrophy. J Neurol Neurosurg Psychiatry. 1986;49:77–86.PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    Auré K, de Baulny HO, Leforêt P, et al. Chronic progressive ophthalmoplegia with large-scale MtDNA rearrangement: can we predict progression? Brain. 2007;130:1516–24.PubMedCrossRefGoogle Scholar
  20. 20.
    Autti TH, Hämäläinen J, Mannerkoski M, et al. JNCL patients show marked brain volume alterations on longitudinal MRI in adolescence. J Neurol. 2008;255:1226–30.PubMedCrossRefGoogle Scholar
  21. 21.
    Bachynski BN, Flynn JT, Rodrigues MM, et al. Hyperglycemic acidotic coma and death in Kearns-Sayre syndrome. Ophthalmology. 1986;93:391–6.PubMedCrossRefGoogle Scholar
  22. 22.
    Baram TZ, Goldman AM, Percy AK. Krabbe disease: specific MRI and CT findings. Neurology. 1986;36:111–5.PubMedCrossRefGoogle Scholar
  23. 23.
    Barkovich AJ. Pediatric neuroimaging. 2nd ed. New York: Raven; 1995. p. 55–105.Google Scholar
  24. 24.
    Barkovich AJ. Magnetic resonance imaging has revolutionized the diagnosis of white matter disorders in children and adults; Myelin mishaps. Ann Neurol. 2006;62:107–8.CrossRefGoogle Scholar
  25. 25.
    Barkovich AJ, Ferriero DM, Bass N, Boyer R. Involvement of the pontomedullary corticospinal tracts: a useful finding in the diagnosis of X-linked adrenoleukodystrophy. AJNR Am J Neuroradiol. 1997;18:95–100.PubMedGoogle Scholar
  26. 26.
    Barkovich AJ, Good WV, Koch TK, et al. Mitochondrial disorders: analysis of their clinical and imaging characteristics. AJNR Am J Neuroradiol. 1993;14:1119–37.PubMedGoogle Scholar
  27. 27.
    Bass NH, Witmer EJ, Dreifuss FE. A pedigree study of metachromatic leukodystrophy: biochemical identification of a carrier state. Neurology. 1970;20:52–62.PubMedCrossRefGoogle Scholar
  28. 28.
    Bassen FA, Kornzweig AL. Malformation of the erythrocytes in the case of atypical retinitis pigmentosa. Blood. 1950;5:381–7.PubMedGoogle Scholar
  29. 29.
    Bateman JB, Philippart M. Ocular features of the Hagberg-Santavuori syndrome. Am J Ophthalmol. 1986;102:262–71.PubMedCrossRefGoogle Scholar
  30. 30.
    Bateman JB, Philippart M, Isenberg SJ. Ocular features of multiple sulfatase deficiency and a new variant of metachromatic leukodystrophy. J Pediatr Ophthalmol Strabismus. 1984;21:133–40.PubMedGoogle Scholar
  31. 31.
    Battaglia A, Harden A, Pampiglione G, et al. Adrenoleukodystrophy: neurophysiological aspects. J Neurol Neurosurg Psychiatry. 1981;44:781–5.PubMedPubMedCentralCrossRefGoogle Scholar
  32. 32.
    Baumann RJ, Markesbery WR. Santavuori disease: diagnosis by leukocyte ultrastructure. Neurology. 1982;32:1277–81.PubMedCrossRefGoogle Scholar
  33. 33.
    Baumeister FA, Auer DP, Hörtnagel K, et al. The eye-of-the-tiger-sign is not a reliable disease marker for Hallervorden-Spatz syndrome. Neuropediatrics. 2005;36:221–2.PubMedCrossRefGoogle Scholar
  34. 34.
    Beaudoin D, Hagenzieker J, Jack R. Neuronal ceroid lipofuscinosis: what are the roles of electron microscopy, DNA and enzyme analysis in diagnosis? J Histotechnol. 2004;27:237–43.CrossRefGoogle Scholar
  35. 35.
    Beck M. Papilloedema in association with Hunter’s syndrome. Br J Ophthalmol. 1983;67:174–7.PubMedPubMedCentralCrossRefGoogle Scholar
  36. 36.
    Beck M, Cole G. Disc oedema in association with Hunter’s syndrome: ocular histopathological findings. Br J Ophthalmol. 1984;68:590–4.PubMedPubMedCentralCrossRefGoogle Scholar
  37. 37.
    Begeer JH, Haaxma R, Snoek JW, et al. Signs of focal posterior cerebral abnormality in early subacute sclerosing panencephalitis. Ann Neurol. 1986;19:200–2.PubMedCrossRefGoogle Scholar
  38. 38.
    Berger J, Moser H, Forss-Petterr S. Leukodystrophies: recent developments in genetics, molecular biology, pathogenesis and treatment. Curr Opin Neurol. 2001;14:305–12.PubMedCrossRefGoogle Scholar
  39. 39.
    Berginer VM, Berginer J, Korezyn AD, et al. Magnetic resonance imaging in cerebrotendinous xanthomatosis: a prospective clinical and neuroradiological study. J Neurol Sci. 1994;122:102–8.PubMedCrossRefGoogle Scholar
  40. 40.
    Biancheri R, Zara F, Bruno C, et al. Phenotypic characterization of hypomyelination and congenital cataracts. Ann Neurol. 2007;62:121–7.PubMedCrossRefGoogle Scholar
  41. 41.
    Biffi A, Montini E, Lorioli L, et al. Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science. 2013;341:864.CrossRefGoogle Scholar
  42. 42.
    Biousse V, Newman NJ. Neuro-ophthalmology of mitochondrial diseases. Curr Opin Neurol. 2003;16:35–43.PubMedCrossRefGoogle Scholar
  43. 43.
    Blieden LC, Desnick RJ, Carter JB, et al. Cardiac involvement in Sandhoff’s disease: inborn error of glycosphingolipid metabolism. Am J Cardiol. 1974;34:83–8.PubMedCrossRefGoogle Scholar
  44. 44.
    Boehme DH, Cottrell JC, Leonberg SC, et al. A dominant form of neuronal ceroid-lipofuscinosis. Brain. 1971;94:745–60.PubMedCrossRefGoogle Scholar
  45. 45.
    Bohlega S, Kambouris M, Shahid M, et al. Gaucher disease with oculomotor apraxia and cardiovascular calcification (Gaucher type IIIC). Neurology. 2000;54:261–3.PubMedCrossRefGoogle Scholar
  46. 46.
    Borzog S, Ramirez-Montealegre D, Chung M, Pearce DA. Juvenile neuronal ceroid lipofuscinosis (JCNL) and the eye. Surv Ophthalmol. 2009;54:463–71.CrossRefGoogle Scholar
  47. 47.
    Bouchard JP, Barbeau A, Bouchard R, Bouchard RW. Autosomal recessive spastic ataxia of Charlevoix-Saguenay. Can J Neurol Sci. 1978;5:61–9.PubMedGoogle Scholar
  48. 48.
    Bouchet C, Steffann J, Corcos J, et al. Prenatal diagnosis of myopathy, encephalopathy, lactic acidosis, and stroke-like syndrome: contribution to understanding mitochondrial DNA segregation during human embryofetal development. J Med Genet. 2006;43:788–92.PubMedPubMedCentralCrossRefGoogle Scholar
  49. 49.
    Boyce WT. Fostering early brain development. JAMA. 2015;169:211–9.Google Scholar
  50. 50.
    Brenner M, Johnson AB, Boespflug-Tanguy O, et al. Mutations in GFAP, encoding glial fibrillary acidic protein, are associated with Alexander’s disease. Nat Genet. 2001;27:117–20.PubMedCrossRefGoogle Scholar
  51. 51.
    Brismar J, Brismar G, Gascon G, et al. Canavan disease: CT and MR imaging of the brain. AJNR Am J Neuroradiol. 1990;11:805–10.PubMedGoogle Scholar
  52. 52.
    Brismar J, Gascon GG, von Steyern KV, et al. Subacute sclerosing panencephalitis: evaluation with CT and MR. AJNR Am J Neuroradiol. 1996;17:761–72.PubMedGoogle Scholar
  53. 53.
    Broadhead DM, Kirk JM, Burt AJ, et al. Full expression of Hunter’s disease in a female with an x-chromosome deletion leading to nonrandom inactivation. Clin Genet. 1986;30:392–8.PubMedCrossRefGoogle Scholar
  54. 54.
    Brodsky MC, Hunter JS. Positional ocular flutter and thickened optic nerves as sentinel signs of Krabbe disease. J AAPOS. 2011;15:595–7.PubMedCrossRefGoogle Scholar
  55. 55.
    Bronson RT, Lake BD, Cook S, et al. Motor neuron degeneration of mice is a model of neuronal ceroid lipofuscinosis (Batten’s disease). Ann Neurol. 1993;33:381–5.PubMedCrossRefGoogle Scholar
  56. 56.
    Brownstein S, Meagher-Villemure K, Polomeno RC, et al. Optic nerve and globoid leukodystrophy (Krabbe’s disease). Arch Ophthalmol. 1978;96:864–70.PubMedCrossRefGoogle Scholar
  57. 57.
    Bussiére M, Kotylak T, Naik K, Levin S. Optic nerve enlargement associated with globoid cell leukodystrophy. Can J Neurol Sci. 2006;33:235–6.PubMedCrossRefGoogle Scholar
  58. 58.
    Carbone AO, Petrozzi CF. Gaucher’s disease: case report with stress on eye findings. Henry Ford Hosp Med J. 1968;16:55–60.PubMedGoogle Scholar
  59. 59.
    Carpenter S, Karpati G, Andermann E. Specific involvement of muscle, nerve, and skin in late infantile and juvenile amaurotic idiocy. Neurology. 1972;22:170–86.PubMedCrossRefGoogle Scholar
  60. 60.
    Carr RE, Siegel IM. Visual electrodiagnostic testing: a practical guide for the clinician. Baltimore: Williams & Wilkins; 1982. p. 1–33.Google Scholar
  61. 61.
    Caruso RC, Kaiser-Kupfer MI, Muenzer J, et al. Electroretinographic findings in the mucopolysaccharidoses. Ophthalmology. 1986;93:1612–6.PubMedCrossRefGoogle Scholar
  62. 62.
    Case records of the Massachusetts general hospital. N Engl J Med. 1998;1914–24.Google Scholar
  63. 63.
    Casteels I, Spillers W, Swinnen T, et al. Optic atrophy as the presenting sign in Hallervorden-Spatz syndrome. Neuropediatrics. 1994;25:265–7.PubMedCrossRefGoogle Scholar
  64. 64.
    Castillo M, Kwock L, Green C. MELAS syndrome: imaging and proton MR spectroscopic findings. AJNR Am J Neuroradiol. 1995;16:233–9.PubMedGoogle Scholar
  65. 65.
    Cavanagh N, Kendall B. High density on computed tomography in infantile Krabbe’s disease: a case report. Dev Med Child Neurol. 1986;28:799–802.PubMedCrossRefGoogle Scholar
  66. 66.
    Chabria S, Tomasi LG, Wong PW. Ophthalmoplegia and bulbar palsy in variant form of maple syrup urine disease. Ann Neurol. 1979;6:71–2.CrossRefGoogle Scholar
  67. 67.
    Charrow J, Esplin JA, Gribble TJ. Gaucher disease: recommendations on diagnosis, evaluation, and monitoring. Arch Intern Med. 1998;158:1754–8.PubMedCrossRefGoogle Scholar
  68. 68.
    Chase DS, Morris AH, Ballabio A, et al. Genetics of Hunter syndrome: carrier detection, new mutations, segregation and linkage analysis. Ann Hum Genet. 1986;50:349–60.PubMedCrossRefGoogle Scholar
  69. 69.
    Chen V. Dietary treatment proposed for Canavan’s disease. Lancet Neurol. 2005;4:273.PubMedCrossRefGoogle Scholar
  70. 70.
    Chu FC, Rodrigues MM, Cogan DG, Barranger JA. The pathology of pingueculae in Gaucher’s disease. Ophthalmic Paediatr Genet. 1984;4:7–11.PubMedCrossRefGoogle Scholar
  71. 71.
    Cogan DG, Chu FC, Barranger J, et al. Macula halo syndrome. Variant of Niemann-Pick disease. Arch Ophthalmol. 1983;101:1698–7000.PubMedCrossRefGoogle Scholar
  72. 72.
    Cogan DG, Chu FC, Gittinger J, et al. Fundal abnormalities of Gaucher’s disease. Arch Ophthalmol. 1980;98:2202–3.PubMedCrossRefGoogle Scholar
  73. 73.
    Cogan DG, Chu FC, Reingold D, et al. Ocular motor signs in some metabolic diseases. Arch Ophthalmol. 1981;99:1802–8.PubMedCrossRefGoogle Scholar
  74. 74.
    Cogan DG, Kawabora T. Histochemistry of the retina in Tay-Sachs disease. Arch Ophthalmol. 1959;61:414–23.CrossRefGoogle Scholar
  75. 75.
    Cogan DG, Kawabora T, Moser H. Metachromatic leukodystrophy. Ophthalmologica. 1970;80:2–17.CrossRefGoogle Scholar
  76. 76.
    Cogan DG, Rodrigues M, Chu FC, et al. Ocular abnormalities in abetalipoproteinemia: a clinicopathologic correlation. Ophthalmology. 1984;91:991–8.PubMedCrossRefGoogle Scholar
  77. 77.
    Collins J, The International Batten Disease Consortium. Isolation of a novel gene underlying Batten disease. CLN3. Cell. 1995;82:949–57.CrossRefGoogle Scholar
  78. 78.
    Collins J, Holder GE, Herbert H, et al. Batten disease: features to facilitate early diagnosis. Br J Ophthalmol. 2006;90:1119–24.PubMedPubMedCentralCrossRefGoogle Scholar
  79. 79.
    Collins ML, Traboulsi EI, Maumenee IH. Optic nerve head swelling and optic atrophy in the systemic mucopolysaccharidoses. Ophthalmology. 1990;97:1445–9.PubMedCrossRefGoogle Scholar
  80. 80.
    Connell P, McCreery K, Doyle A, et al. Central corneal thickness and its relationship to intraocular pressure in mucopolysaccharidoses-1 following bone marrow transplantation. J AAPOS. 2008;12:7010.CrossRefGoogle Scholar
  81. 81.
    Conzelmann E, Sandhoff K. AB variant of infantile Gm2-gangliosidosis: deficiency of a factor necessary for stimulation of hexosaminidase A-catalyzed degradation of ganglioside Gm2 and glycolipid Ga2. Proc Natl Acad Sci U S A. 1978;75:3979–83.PubMedPubMedCentralCrossRefGoogle Scholar
  82. 82.
    Cooper J. Progress toward understanding the neurobiology of Batten disease or neuronal ceroid lipofuscinosis. Curr Opin Neurol. 2003;16:121–8.PubMedCrossRefGoogle Scholar
  83. 83.
    Copenhaver RM, Goodman G. The electroretinogram in infantile, late infantile, and juvenile amaurotic familial idiocy. Arch Ophthalmol. 1960;63:559–66.PubMedCrossRefGoogle Scholar
  84. 84.
    Courtney RJ, Pennesi ME. Interval spectral-domain optical coherence tomography and electrophysiology findings in neonatal adrenoleukodystrophy. JAMA Ophthalmol. 2013;131:808–10.CrossRefGoogle Scholar
  85. 85.
    Coussa RG, Roos JCP, Aroichane M, et al. Progression of retinal changes in Gaucher disease: a case report. Eye (Lond). 2013;27:1331–3.CrossRefGoogle Scholar
  86. 86.
    Cox CS, Dubey P, Raymond GV, et al. Cognitive evaluation of neurologically-asymptomatic boys with x-linked adrenal leukodystrophy. Arch Neurol. 2006;63:69–73.PubMedCrossRefGoogle Scholar
  87. 87.
    Crisi G, Ferrari G, Merelli E, et al. MRI in a case of Kearns-Sayre syndrome confirmed by molecular analysis. Neuroradiology. 1994;36:37–8.PubMedCrossRefGoogle Scholar
  88. 88.
    Cruysberg JR, Wevers RA, van Engelen BG, et al. Ocular and systemic manifestations of cerebrotendinous xanthomatosis. Am J Ophthalmol. 1995;120:597–604.PubMedCrossRefGoogle Scholar
  89. 89.
    Dabbagh O, Swaiman KF. Cockayne syndrome: MRI correlates of hypomyelination. Pediatr Neurol. 1988;4:113–6.PubMedCrossRefGoogle Scholar
  90. 90.
    Dangel ME, Tsou BH. Retinal involvement in Morquio’s syndrome (MPS IV). Ann Ophthalmol. 1985;17:349–54.PubMedGoogle Scholar
  91. 91.
    Danks DM, Cartwright E, Stevens BJ, et al. Menkes’ kinky hair disease: further definition of the defect in copper transport. Science. 1973;179:1140–2.PubMedCrossRefGoogle Scholar
  92. 92.
    Darin N, Oldfors A, Moslemi A-R, et al. The incidence of mitochondrial encephalomyopathies in childhood: clinical features and morphological, biochemical, and DNA abnormalities. Ann Neurol. 2001;49:377–83.PubMedCrossRefGoogle Scholar
  93. 93.
    Daroff R. CPEO in Kearns-Sayre syndrome: an update. North American Neuro-Ophthalmology Society Meeting, Cancun, Mexico; 1989.Google Scholar
  94. 94.
    Dawson Jr JR. Cellular inclusions in cerebral lesions of lethargic encephalitis. Am J Pathol. 1933;9:7–16.PubMedPubMedCentralGoogle Scholar
  95. 95.
    Debray FG, Lambert M, Chevalier I, et al. Long-term outcome and clinical spectrum of 73 pediatric patients with mitochondrial diseases. Pediatrics. 2007;119:722–33.PubMedCrossRefGoogle Scholar
  96. 96.
    Demaerel P, Kendall BE, Kingsley D. Cranial CT and MRI in diseases with DNA repair defects. Neuroradiology. 1992;34:117–21.PubMedCrossRefGoogle Scholar
  97. 97.
    Demange P, Gia HP, Kalifa G, et al. MR of Kearns-Sayre syndrome. AJNR Am J Neuroradiol. 1989;10(5 Suppl):S91.PubMedGoogle Scholar
  98. 98.
    Deprez M, D’Houghe M, Misson JP, et al. Infantile and juvenile presentations of Alexander’s disease: a report of two cases. Acta Neurol Scand. 1999;99:158–65.PubMedCrossRefGoogle Scholar
  99. 99.
    Detre JA, Wang ZY, Bogdan AR, et al. Regional variation in brain lactate in Leigh syndrome by localized 1H magnetic resonance spectroscopy. Ann Neurol. 1991;29:218–21.PubMedCrossRefGoogle Scholar
  100. 100.
    Deutsch JA, Asbell PA. Sialidosis and galactosialidosis. In: Gold DH, Weingeist TA, editors. The eye in systemic disease. Philadelphia: J.B. Lippincott; 1990. p. 376–7.Google Scholar
  101. 101.
    Dickinson JP, Holton JB, Lewis GM, et al. Maple syrup urine disease: four years’ experience with dietary treatment of a case. Acta Paediatr Scand. 1969;58:341–51.PubMedCrossRefGoogle Scholar
  102. 102.
    DiMauro S, Bonilla E. Mitochondrial encephalomyopathies. In: Rosenberg RN, Pruisiner SB, DiMauro S, et al., editors. The molecular and genetic basis of neurological disease. Boston: Butterworth Heinemann; 1997. p. 201–35.Google Scholar
  103. 103.
    Dinda AK, Sarkar C, Roy S. Rosenthal fibers: an immunohistochemical, ultrastructural and immunoelectron microscopic study. Acta Neuropathol. 1990;79:456–60.PubMedCrossRefGoogle Scholar
  104. 104.
    Dollfus H, Porto F, Caussade P, et al. Ocular manifestations in the inherited DNA repair disorders. Surv Ophthalmol. 2003;48:107–22.PubMedCrossRefGoogle Scholar
  105. 105.
    Dooling EC, Schoene WC, Richardson Jr EP. Hallervorden-Spatz syndrome. Arch Neurol. 1974;30:70–83.PubMedCrossRefGoogle Scholar
  106. 106.
    Drack AV, Miller JN, Pearce DA. A novel c.1135_1138delCTGT mutation in CLN3 leads to juvenile neuronal ceroid lipofuscinosis. J Child Neurol. 2013;28:1112–6.PubMedCrossRefGoogle Scholar
  107. 107.
    Dubey P, Fatemi A, Barker PB, et al. Spectroscopic evidence of cerebral axonopathy in patients with “pure” adrenomyeloneuropathy. Neurology. 2005;64:304–10.PubMedCrossRefGoogle Scholar
  108. 108.
    Duffner PK, Barczykowski A, Kay DM, et al. Later onset phenotypes of Krabbe disease: results of the world-wide registry. Pediatr Neurol. 2012;46:298–306.PubMedCrossRefGoogle Scholar
  109. 109.
    Duker JS, Belmont J, Bosley TM. Angioid streaks associated with abetalipoproteinemia. Case report. Arch Ophthalmol. 1987;105:1173–4.PubMedCrossRefGoogle Scholar
  110. 110.
    Duquette A, Brais B, Bouchard J-P, Mathieu J. Clinical presentation and evolution of spastic ataxia of Charlevoix-Saguenay. Mov Disord. 2013;28:2011–4.PubMedCrossRefGoogle Scholar
  111. 111.
    Dyke JP, Sondhi D, Voss HU, et al. Assessment of disease severity in late infantile neuronal ceroid lipofuscinosis using multiparametric MR imaging. AJNR Am J Neuroradiol. 2013;34:884–9.PubMedCrossRefGoogle Scholar
  112. 112.
    Dyken PR. Subacute sclerosing panencephalitis. Current status. Neurol Clin. 1985;3:179–96.PubMedGoogle Scholar
  113. 113.
    Egan RA, Weleber RG, Hogarth P, et al. Neuro-ophthalmologic and electroretinographic findings in pantothenate kinase-associated neurodegeneration (formerly Hallervorden-Spatz syndrome). Am J Ophthalmol. 2005;140:267–74.PubMedPubMedCentralCrossRefGoogle Scholar
  114. 114.
    Eichler F, Grodd W, Grant E, et al. Metachromatic leukodystrophy: natural course of cerebral MRI changes in relation to clinical course. J Inherit Metab Dis. 2011;34:1095–102.CrossRefGoogle Scholar
  115. 115.
    Ek J, Kase BF, Reith A, et al. Peroxisomal dysfunction in a boy with neurologic symptoms and amaurosis (Leber disease): clinical and biochemical findings similar to those observed in Zellweger syndrome. J Pediatr. 1986;108:19–24.PubMedCrossRefGoogle Scholar
  116. 116.
    Elsås T, Rinck PA, Isaksen C, et al. Cerebral nuclear magnetic resonance (MRI) in Kearns syndrome. Acta Ophthalmol (Copenh). 1988;66:469–73.CrossRefGoogle Scholar
  117. 117.
    Emery JM, Green WR, Wyllie RG, et al. GM1-gangliosidosis. Ocular and pathological manifestations. Arch Ophthalmol. 1971;85:177–87.PubMedCrossRefGoogle Scholar
  118. 118.
    Engert JX, Berube P, Mercier J, et al. ARSACS, a spastic ataxia common in northeastern Quebec, is caused by mutations in a new gene encoding an 11.5-kb ORF. Nat Genet. 2000;24:120–5.PubMedCrossRefGoogle Scholar
  119. 119.
    Erikson A. Gaucher disease-Norrbottnian Type III. Acta Paediatr Scand Suppl. 1986;326:1–42.PubMedCrossRefGoogle Scholar
  120. 120.
    Fahnehjelm KT, Holmström G, Ying L, et al. Ocular characteristics in 10 children with long-chain 3-Hydroxyacyl-CoA dehydrogenase deficiency: a cross-sectional study with long-term follow-up. Acta Ophthalmol. 2008;86:329–37.PubMedCrossRefGoogle Scholar
  121. 121.
    Fang W, Huang CC, Lee CC, et al. Ophthalmologic manifestation in MELAS syndrome. Arch Neurol. 1993;50:977–80.PubMedCrossRefGoogle Scholar
  122. 122.
    Farley TJ, Ketonen LM, Bodensteiner JB, et al. Serial MRI and CT findings in infantile Krabbe disease. Pediatr Neurol. 1992;8:455–8.PubMedCrossRefGoogle Scholar
  123. 123.
    Farrell K, Chuang S, Becker LE. Computed tomography in Alexander’s disease. Ann Neurol. 1984;15:605–7.PubMedCrossRefGoogle Scholar
  124. 124.
    Farrell DF. Neonatal adrenoleukodystrophy: a clinical, pathological, and biochemical study. Pediatr Neurol. 2012;47:330–6.PubMedCrossRefGoogle Scholar
  125. 125.
    Farrell DF, MacMartin MP, Clark AF. Multiple molecular forms of arylsulfatase A in different forms of metachromatic leukodystrophy (MLD). Neurology. 1979;29:16–20.PubMedCrossRefGoogle Scholar
  126. 126.
    Feanny SJ, Chuang SH, Becker LE, et al. Intracerebral paraventricular hyperdensities: a new CT sign in Krabbe globoid cell leukodystrophy. J Inherit Metab Dis. 1987;10:24–7.Google Scholar
  127. 127.
    Feigin I, Pena CE, Budzilovich G. The infantile spongy degenerations. Neurology. 1968;18:153–66.PubMedCrossRefGoogle Scholar
  128. 128.
    Feliciani M, Curatolo P. Early clinical and imaging (high-field MRI) diagnosis of Hallervorden-Spatz disease. Neuroradiology. 1994;36:247–8.PubMedCrossRefGoogle Scholar
  129. 129.
    Fenichel GM. Clinical pediatric neurology: a symptom and sign approach. 2nd ed. Philadelphia: W.B. Saunders; 1993.Google Scholar
  130. 130.
    Fettes I, Killinger D, Volpe R. Adrenoleukodystrophy: report of a familial case. Clin Endocrinol (Oxf). 1979;11:151–60.CrossRefGoogle Scholar
  131. 131.
    Fishman MA. Disorders primarily of white matter. In: Swaiman KF, editor. Pediatric neurology, principles and practice, vol. 2. St. Louis: C.V. Mosby; 1994. p. 999–1017.Google Scholar
  132. 132.
    Fitzgibbon E. Eye movements in Niemann Pick C disease. Proceedings of the North American Neuro-Ophthalmology Society. Orlando; 2008, Mar 8–13.Google Scholar
  133. 133.
    Fiumara A, Barone R, Buttitta P, et al. Carbohydrate deficient glycoprotein syndrome type 1a: ophthalmologic aspects in four Sicilian patients. Br J Ophthalmol. 1994;78:845–6.PubMedPubMedCentralCrossRefGoogle Scholar
  134. 134.
    Folz SJ, Trobe JD. The peroxisome and the eye. Surv Ophthalmol. 1991;35:353–68.PubMedCrossRefGoogle Scholar
  135. 135.
    Font RL, Jenis EH, Tuck KD. Measles maculopathy associated with subacute sclerosing panencephalitis: immunofluorescent and immuno-ultrastructural studies. Arch Pathol. 1973;96:168–74.PubMedGoogle Scholar
  136. 136.
    Francke U. The human gene for beta glucuronidase is on chromosome 7. Am J Hum Genet. 1976;28:357–62.PubMedPubMedCentralGoogle Scholar
  137. 137.
    Fratter C, Gorman GS, Stewart JD, et al. The clinical, histochemical, and molecular spectrum of PEO1 (Twinkle)-linked adPEO. Neurology. 2010;74:619–26.CrossRefGoogle Scholar
  138. 138.
    Friend SH, Schadt EE. Clues from the resilient. Science. 2014;344:970–3.PubMedCrossRefGoogle Scholar
  139. 139.
    Frisch IB, Haag P, Steffen H, et al. Kjellin’s syndrome: autofluorescence, angiographic, and electrophysiologic findings. Ophthalmology. 2002;109:1484–91.PubMedCrossRefGoogle Scholar
  140. 140.
    Fuijkschot J, Cruysberg JRM, Willemsen MA, et al. Subclinical changes in the juvenile crystalline macular dystrophy in Sjögren-Larsson syndrome detected by optical coherence tomography. Ophthalmology. 2008;115:870–5.PubMedCrossRefGoogle Scholar
  141. 141.
    Gandhi R, Kakkar R, Rajan S. Menkes kinky hair syndrome: a rare neurodegenerative disease. Case Rep Radiol. 2012;2012, 684309. doi: 10.1155/2012/684309.PubMedPubMedCentralGoogle Scholar
  142. 142.
    Garavelli L, Rosato S, Mele A, et al. Massive hemobilia and papillomatosis of the gallbladder in metachromatic leukodystrophy: a life threatening condition. Neuropediatrics. 2009;40:284–96.PubMedCrossRefGoogle Scholar
  143. 143.
    Gardner-Thorpe C, Kocen RS. Subacute sclerosing panencephalitis presenting as transient homonymous hemianopia. J Neurol Neurosurg Psychiatry. 1983;46:186–7.PubMedPubMedCentralCrossRefGoogle Scholar
  144. 144.
    Gasch AT, Caruso RC, Kaler SG, Kaiser-Kupfer M. Menkes’ syndrome: ophthalmic findings. Ophthalmology. 2002;109:1477–83.PubMedCrossRefGoogle Scholar
  145. 145.
    Inflammatory diseases of the retina and choroid. In: Gass JDM, editor. Stereoscopic atlas of macular diseases: diagnosis and treatment, vol. 2. St. Louis: C.V. Mosby; 1987:455–549.Google Scholar
  146. 146.
    Heredodystrophic disorders affecting the pigment epithelium and retina. In: Gass JDM, editor. Stereoscopic atlas of macular diseases: diagnosis and treatment, vol. 2. St. Louis: C.V. Mosby; 1987:312.Google Scholar
  147. 147.
    Heredodystrophic disorders affecting the pigment epithelium and retina. In: Gass JDM, editor. Stereoscopic atlas of macular diseases: diagnosis and treatment, vol. 2. St. Louis: C.V. Mosby; 1987:316.Google Scholar
  148. 148.
    Heredodystrophic disorders affecting the pigment epithelium and retina. In: Gass JDM, editor. Stereoscopic atlas of macular diseases: diagnosis and treatment, vol. 2. St. Louis: C.V. Mosby; 1987:310.Google Scholar
  149. 149.
    Genetics home reference: your guide to understanding genetic conditions. Lister Hill National Center for Biomedical Communications, National Institutes of Health. Accessed 9 Jul 2008.
  150. 150.
    Germain DP. Gaucher disease: a paradigm for interventional genetics. Clin Genet. 2004;65:77–86.PubMedCrossRefGoogle Scholar
  151. 151.
    Gerth C, Morel CF, Feigenbaum A, et al. Ocular phenotype in patients with methylmalonic aciduria and homocystinuria, cobalamin C type. J AAPOS. 2008;12:591–6.PubMedCrossRefGoogle Scholar
  152. 152.
    Giagheddu M, Tamburini G, Piga M, et al. Comparison of MRI, EEG, Eps and ECD-SPECT in Wilson’s disease. Acta Neurol Scand. 2001;3:71–81.CrossRefGoogle Scholar
  153. 153.
    Gills JP, Hobson R, Hanley WB, et al. Electroretinography and fundus oculi findings in Hurler’s disease and allied mucopolysaccharidoses. Arch Ophthalmol. 1965;74:596–603.PubMedCrossRefGoogle Scholar
  154. 154.
    Girard M, Lariviere R, Parfitt DA, et al. Mitochondrial dysfunction and Purkinje cell loss in autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS). Proc Natl Acad Sci U S A. 2012;109:1661–6.PubMedPubMedCentralCrossRefGoogle Scholar
  155. 155.
    Gizicki R, Robert M-C, Gómez-López L, et al. Long-term visual outcome of methylmalonic aciduria and homocystinuria, cobalamin C type. Ophthalmology. 2014;121:381–4.PubMedCrossRefGoogle Scholar
  156. 156.
    Godel V, Blumenthal M, Goldman B, et al. Visual functions in Tay-Sachs disease patients following enzyme replacement therapy. Metab Ophthalmol. 1978;2:27–32.Google Scholar
  157. 157.
    Goebel H. Symposium: the neuronal ceroid-lipofuscinoses (NCL)—a group of lysosomal disorders come of age. Introduction. Brain Pathol. 2004;14:59–60.Google Scholar
  158. 158.
    Goebel HH, Bode G, Caesar R, et al. Bulbar palsy with Rosenthal fiber formation in the medulla of a 15-year-old girl. Localized form of Alexander’s disease? Neuropediatrics. 1981;12:382–91.PubMedCrossRefGoogle Scholar
  159. 159.
    Goebel H, Wisniewski K. Symposium: the neuronal ceroid-lipofuscinoses (NCL): a group of lysosomal storage diseases come of age. Current state of clinical and morphological features in human NCL. Brain Pathol. 2004;14:61–9.PubMedCrossRefGoogle Scholar
  160. 160.
    Goldberg MF, Cotlier E, Fischenscher LG, et al. Macular cherryred spot, corneal clouding, and betagalactosidase deficiency. Arch Intern Med. 1971;128:387.PubMedCrossRefGoogle Scholar
  161. 161.
    Goldfischer S, Collins J, Rapin I, et al. Peroxisomal defects in neonatal-onset and X-linked adrenoleukodystrophies. Science. 1985;227:67–70.PubMedCrossRefGoogle Scholar
  162. 162.
    Good WV, Crain LS, Quint RD, et al. Overlooking: a sign of bilateral central scotomata in children. Dev Med Child Neurol. 1992;34:69–73.PubMedCrossRefGoogle Scholar
  163. 163.
    Goto Y, Horai S, Matsuoka T, et al. Mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS): a correlative study of the clinical features in mitochondrial DNA mutation. Neurology. 1992;42:545–50.Google Scholar
  164. 164.
    Grafe M, Thomas C, Schneider J, et al. Infantile Gaucher’s disease: a case with neuronal storage. Ann Neurol. 1988;23:300–3.PubMedCrossRefGoogle Scholar
  165. 165.
    Green SH, Wirtschafter JD. Ophthalmoscopic findings in subacute sclerosing panencephalitis. Br J Ophthalmol. 1973;57:780–7.PubMedPubMedCentralCrossRefGoogle Scholar
  166. 166.
    Gregory A, Hayflick SJ. Pantothenate kinase-associated neurodegeneration. In: Pagon RA, Bird TD, Dolan CR, Stephens K, Adam MP, editors. GeneReviews (Internet). Seattle: University of Washington, Seattle; 1993. Accessed 31 Jan 2013.Google Scholar
  167. 167.
    Grimm G, Prayer L, Oder W, et al. Comparison of functional and structural brain disturbances in Wilson disease. Neurology. 1991;41:272–6.PubMedCrossRefGoogle Scholar
  168. 168.
    Gropman AL. The neurological presentations of childhood and adult mitochondrial disease: established syndromes and phenotypic variations. Mitochondrion. 2004;4(5–6):503–20.PubMedCrossRefGoogle Scholar
  169. 169.
    Gullerman RP. The eye-of-the-tiger sign. Radiology. 2000;2127:895–6.CrossRefGoogle Scholar
  170. 170.
    Gullingsrud EO, Krivit W, Summers CG. Ocular abnormalities in the mucopolysaccharidoses after bone marrow transplantation. Longer follow up. Ophthalmology. 1998;105:1099–105.PubMedCrossRefGoogle Scholar
  171. 171.
    Gupta N, Henry RG, Strober J, et al. Neural stem cell engraftment and myelination in the human brain. Sci Transl Med. 2012;4:155ra137.PubMedPubMedCentralCrossRefGoogle Scholar
  172. 172.
    Hagenfeldt L, von Döbeln U, Holme E, et al. 3-Hydroxydicarboxylic aciduria–a fatty acid oxidation defect with severe prognosis. J Pediatr. 1990;116:387–92.PubMedCrossRefGoogle Scholar
  173. 173.
    Hall CW, Liebars I, Dinatale P, et al. Enzymatic diagnosis of the genetic leuco-polysaccharide storage disorders. Methods Enzymol. 1978;50:439–56.PubMedCrossRefGoogle Scholar
  174. 174.
    Hallervorden J. Uber eine familiare Erkrankung im extrapyramidal System. Dtsch Z Nervenheilkd. 1924;81:204–10.CrossRefGoogle Scholar
  175. 175.
    Hallervorden J, Spatz H. Eigenartige Erkrankung im extrapyramidalen System mit besonderer Beteiligung des Globus Pallidus und der Substantia nigra. Z Ges Neurol Psychiatr. 1922;79:254–302.CrossRefGoogle Scholar
  176. 176.
    Hammans SR, Sweeney MG, Brockington M, et al. The mitochondrial DNA transfer RNA-LysA → G(8344) mutation and the syndrome of myoclonic epilepsy with ragged-red fibers (MERRF). Relationship of clinical phenotype to proportion of mutant mitochondrial DNA. Brain. 1991;116:617–32.CrossRefGoogle Scholar
  177. 177.
    Harcourt B, Ashton N. Ultrastructure of the optic nerve in Krabbe’s leukodystrophy. Br J Ophthalmol. 1973;57:885–91.PubMedPubMedCentralCrossRefGoogle Scholar
  178. 178.
    Harden A, Adams GG, Taylor DS. The electroretinogram. Arch Dis Child. 1989;64:1080–7.PubMedPubMedCentralCrossRefGoogle Scholar
  179. 179.
    Harding SA, Nischal KK, Upponi-Patil AA, Fowler DJ. Indications and outcome of deep anterior lamellar keratoplasty in children. Ophthalmology. 2010;117:2191–5.PubMedCrossRefGoogle Scholar
  180. 180.
    Harris CM, Taylor DSI, Vellodi A. Ocular motor abnormalities in Gaucher disease. Neuropediatrics. 1999;30:289–93.PubMedCrossRefGoogle Scholar
  181. 181.
    Hayflick SJ, Penzien JM, Michi W, et al. Cranial MRI changes may precede symptoms in Hallervorden-Spatz syndrome. Pediatr Neurol. 2001;25:166–9.PubMedCrossRefGoogle Scholar
  182. 182.
    Hechtman P, Gordon BA. Ng Ying Kin NMK. Deficiency of the hexosaminidase A activator protein in a case of GM2 gangliosidosis; variant AB. Pediatr Res. 1982;16:217–22.PubMedCrossRefGoogle Scholar
  183. 183.
    Henneke M, Combes P, Diekmann S, et al. GJA12 mutations are a rare cause of Pelizaeus-Merzbacher-like disease. Neurology. 2008;70:748–54.PubMedCrossRefGoogle Scholar
  184. 184.
    Henning KA, Li L, Iyer N, et al. The ocular manifestations of the inherited DNA repair disorders. Surv Ophthalmol. 2003;48:107–22.CrossRefGoogle Scholar
  185. 185.
    Herndon RM. Is Alexander’s disease a nosologic entity or a common pathologic pattern of diverse etiology? J Child Neurol. 1999;14:275–6.PubMedCrossRefGoogle Scholar
  186. 186.
    Herndon RM, Rubinstein LJ, Freeman JM, et al. Light and electronic observations on Rosenthal fibers in Alexander’s disease and multiple sclerosis. J Neuropathol Exp Neurol. 1970;29:524–51.PubMedCrossRefGoogle Scholar
  187. 187.
    Heroman JW, Rychwalski P, Barr CC. Cherry red spot in sialidosis (mucolipidosis type 1). Arch Ophthalmol. 2008;126:270–1.PubMedCrossRefGoogle Scholar
  188. 188.
    Hiatt RL, Grizzard HT, McNeer P, et al. Ophthalmologic manifestations of subacute sclerosing panencephalitis. Trans Am Acad Ophthalmol Otolaryngol. 1971;75:344–50.PubMedGoogle Scholar
  189. 189.
    Higgins CF. ABC transporters: from microorganisms to man. Annu Rev Cell Biol. 1992;8:67–113.PubMedCrossRefGoogle Scholar
  190. 190.
    Higgins JJ, Patterson MC, Dambrosia JM, et al. A clinical staging classification for type C Niemann-Pick disease. Neurology. 1992;42:2286–90.PubMedCrossRefGoogle Scholar
  191. 191.
    Hirano M, Pavlakis SG. Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes [MELAS]: current concepts. J Child Neurol. 1994;9:4–13.PubMedCrossRefGoogle Scholar
  192. 192.
    Hitmair K, Wimberger D, Wiesbauer P, et al. Early infantile form of Krabbe’s disease with optic hypertrophy: serial MR examinations and autopsy correlation. AJNR Am J Neuroradiol. 1994;15:1454–8.Google Scholar
  193. 193.
    Hittner HM, Ketzer FL, Mehta RS. Zellweger syndrome: lenticular opacities indicating carrier status and lens abnormalities characteristic of homozygotes. Arch Ophthalmol. 1981;99:1977–82.PubMedCrossRefGoogle Scholar
  194. 194.
    Hobson GM, Garbern JY. Pelizaeus-Merzbacher disease, Pelizaeus-Merzbacher-like disease 1, and related hypomyelinating disorders. Semin Neurol. 2012;32:62–7.PubMedCrossRefGoogle Scholar
  195. 195.
    Hofman IKA, Santavouri P, Gottlob I, et al. The neuronal ceroid lipofuscinosis (Batten disease). Amsterdam: Ios Press; 1999.Google Scholar
  196. 196.
    Hokezu Y, Kuriyama M, Kubota R, et al. Cerebrotendinous xanthomatosis: cranial CT and MRI studies in eight patients. Neuroradiology. 1992;34:308–12.PubMedCrossRefGoogle Scholar
  197. 197.
    Holt IJ, Harding AE, Cooper JM, et al. Mitochondrial myopathies: clinical and biochemical features of 30 patients with major deletions of muscle mitochondrial DNA. Ann Neurol. 1989;26:699–708.PubMedCrossRefGoogle Scholar
  198. 198.
    Honda Y, Sudo M. Electroretinogram and visually evoked cortical potential in Tay-Sachs disease: a report of two cases. J Pediatr Ophthalmol. 1976;13:226–9.PubMedGoogle Scholar
  199. 199.
    Horga A, Pitceathly RD, Blake JC, et al. Peripheral neuropathy predicts nuclear gene defect in patients with mitochondrial ophthalmoplegia. Brain. 2014;137:3200–12.PubMedPubMedCentralCrossRefGoogle Scholar
  200. 200.
    Hormia M. Diffuse cerebral sclerosis, melanoderma and adrenal insufficiency (adrenoleukodystrophy). Acta Neurol Scand. 1978;58:128–33.PubMedCrossRefGoogle Scholar
  201. 201.
    Horvath R. Brain iron takes off: a new propeller protein links neurodegeneration with autophagy. Brain. 2013;136(Pt 6):1687–91.PubMedCrossRefGoogle Scholar
  202. 202.
    Hübner CA, Orth U, Senning A, et al. Seventeen novel PLP1 mutations in patients with Pelizaeus-Merzbacher disease. Hum Mutat. 2005;25:321–2.PubMedCrossRefGoogle Scholar
  203. 203.
    Huppke P, Brendel C, Kalscheuer V, et al. Mutations in SLC33A1 cause a lethal autosomal-recessive disorder with congenital cataracts, hearing loss, and low serum copper and ceruloplasmin. Am J Hum Genet. 2012;90:61–8.PubMedPubMedCentralCrossRefGoogle Scholar
  204. 204.
    Inster-Moati I, Quoc EB, Pless M, et al. Ocular motility in Wilson’s disease: a study on 34 patients. J Neurol Neurosurg Psychiatry. 2007;78:1199–201.CrossRefGoogle Scholar
  205. 205.
    International Batten Disease Consortium. Isolation of a novel gene underlying batten disease. CLN3. Cell. 1995;82:949–57.CrossRefGoogle Scholar
  206. 206.
    Ito S, Shirai W, Asahina M, Hattori T. Clinical and brain MR imaging features focusing on the brain stem and cerebellum in patients with myoclonic epilepsy with ragged-red fibers due to mitochondrial A8344G mutation. AJNR Am J Neuroradiol. 2008;29:392–5.PubMedCrossRefGoogle Scholar
  207. 207.
    Jaben S, Flynn JT. Neuronal ceroid lipofuscinosis (Batten-Vogt’s disease). In: Neuro-Ophthalmology. 1982; Ch. 27.Google Scholar
  208. 208.
    Jaben SL, Flynn JT, Parker JC. Neuronal ceroid lipofuscinosis. Diagnosis from peripheral blood smear. Ophthalmology. 1983;90:1373–7.PubMedCrossRefGoogle Scholar
  209. 209.
    Jacob J, Robertson NJ, Hilton DA, et al. The clinicopathological spectrum of Rosenthal fibre encephalopathy and Alexander’s disease: a case report and review of the literature. J Neurol Neurosurg Psychiatry. 2003;74:807–10.PubMedPubMedCentralCrossRefGoogle Scholar
  210. 210.
    Jacobson DM. Angioid streaks associated with abetalipoproteinemia. Arch Ophthalmol. 1987;105:1173–4.CrossRefGoogle Scholar
  211. 211.
    Jaeken J, Artigas J, Barone R, et al. Phosphomannomutase deficiency is the main cause of carbohydrate-deficient glycoprotein syndrome with type 1 isoelectrofocusing pattern of serum sialotransferrins. J Inherit Metab Dis. 1997;44:109–40.Google Scholar
  212. 212.
    Jain P, Kannan L, Chakrabarty B, et al. Menkes disease—an important cause of early onset refractory seizures. J Pediatr Neurosci. 2014;9:11–6.Google Scholar
  213. 213.
    Jampel RS, Falls HF. Atypical retinitis pigmentosa, acanthocytosis and herido degenerative neuromuscular disease. Arch Ophthalmol. 1958;59:818–20.CrossRefGoogle Scholar
  214. 214.
    Jampel RS, Quaglio ND. Eye movements in Tay-Sachs disease. Neurology. 1964;14:1013–9.PubMedCrossRefGoogle Scholar
  215. 215.
    Janson CG, Assidi M, Francis J, et al. Lithium citrate for Canavan disease. Pediatr Neurol. 2005;33:235–43.PubMedCrossRefGoogle Scholar
  216. 216.
    Johnson AB. Alexander disease. In: Moser HW, editor. Neurodystrophies and neurolipidosis. Handbook of clinical neurology, vol. 66 (revised series 22). Amsterdam: Elsevier; 1996. pp. 701–10.Google Scholar
  217. 217.
    Jones BV, Barron TF, Towflghi J. Optic nerve enlargement in Krabbe’s disease with optic nerve hypertrophy: serial MR examinations and autopsy correlation. AJNR Am J Neuroradiol. 1999;20:1228–31.PubMedGoogle Scholar
  218. 218.
    Kaback MM, Desnick RJ. Tay-Sachs disease: from clinical description to molecular defect. Adv Genet. 2001;44:1–9.PubMedCrossRefGoogle Scholar
  219. 219.
    Kaback M, Lim-Steele J, Dabholkar D, et al. Tay-Sachs disease—carrier screening, prenatal diagnosis, and the molecular era. An international perspective, 1970 to 1993. JAMA. 1993;270:|2307–15.PubMedCrossRefGoogle Scholar
  220. 220.
    Kamata Y, Mashima Y, Yokoyama M, et al. Patient with Kearns-Sayre syndrome exhibiting abnormal magnetic resonance image of the brain. J Neuroophthalmol. 1998;18:284–8.PubMedCrossRefGoogle Scholar
  221. 221.
    Kamate M, Hattiholi V. Punched holes in globus pallidi: a novel neuroimaging finding in Wilson disease. Pediatr Neurol. 2014;50:281–2.PubMedCrossRefGoogle Scholar
  222. 222.
    Käsmann-Kellner B, Weindler J, Pfau B, et al. Ocular changes in mucopolysaccharidosis IV A (Morquio A syndrome) and long-term results of perforating keratoplasty. Ophthalmologica. 1999;213:200–5.PubMedCrossRefGoogle Scholar
  223. 223.
    Kaul R, Balamurugan K, Gao GP, et al. Canavan disease: genomic organization and localization of human ASPA to 17p13-ter: conservation of the ASPA gene during evolution. Genomics. 1994;21:364–70.PubMedCrossRefGoogle Scholar
  224. 224.
    Kaul RK, Gao GP, Balamurugan K, et al. Human aspartoacylase cDNA and missense mutation in Canavan disease. Nat Genet. 1993;5:118–23.PubMedCrossRefGoogle Scholar
  225. 225.
    Kayden HJ, Traber MG. Absorption, lipoprotein transport, and regulation of plasma concentrations of vitamin E in humans. J Lipid Res. 1993;34:343–58.PubMedGoogle Scholar
  226. 226.
    Keane JR. Lid-opening apraxia in Wilson’s disease. J Clin Neuroophthalmol. 1988;8:31–3.PubMedCrossRefGoogle Scholar
  227. 227.
    Kendall BE. Disorders of lysosomes, peroxisomes, and mitochondria. AJNR Am J Neuroradiol. 1992;13:621–53.PubMedGoogle Scholar
  228. 228.
    Keppler K, Cunniff C. Variable presentation of cytochrome c oxidase deficiency. Am J Dis Child. 1992;146:1349–52.PubMedGoogle Scholar
  229. 229.
    Kerrison KB, Biousse V, Newman NJ. Retinopathy of NARP syndrome. Arch Ophthalmol. 2000;118:298–9.PubMedCrossRefGoogle Scholar
  230. 230.
    Khan AO, Aldahmesh MA, Mohamed JY, Alkuraya FS. Juvenile cataract morphology in 3 siblings not yet diagnosed with cerebrotendinous xanthomatosis. Ophthalmology. 2013;120:956–60.PubMedCrossRefGoogle Scholar
  231. 231.
    Kim TJ, Kim IO, Kim WA, et al. MR imaging of the brain in Wilson disease of childhood: findings before and after treatment with clinical correlation. AJNR Am J Neuroradiol. 2006;27:1373–8.PubMedGoogle Scholar
  232. 232.
    King AD, Walshe JM, Kendall BE, et al. Cranial MR imaging in Wilson disease. AJR Am J Roentgenol. 1996;167:1579–84.PubMedCrossRefGoogle Scholar
  233. 233.
    Kirkham TH, Kamin DF. Slow saccadic eye movements in Wilson’s disease. J Neurol Neurosurg Psychiatry. 1974;37:191–4.PubMedPubMedCentralCrossRefGoogle Scholar
  234. 234.
    Kivlin JD, Sanborn GE, Myers GG. The cherry-red spot in Tay-Sachs and other storage diseases. Ann Neurol. 1985;17:356–60.PubMedCrossRefGoogle Scholar
  235. 235.
    Kjellin K. Familial spastic paraplegia with amyotrophy, oligophrenia, and central retinal degeneration. Arch Neurol. 1959;1:133–40.PubMedCrossRefGoogle Scholar
  236. 236.
    Kodama H, Murata Y, Kobayashi M, et al. Clinical manifestations and treatment of Menkes disease and its variants. Pediatr Int. 1999;41:423–9.PubMedCrossRefGoogle Scholar
  237. 237.
    Koga Y, Akita Y, Nishioka J, et al. L-arginine improves the symptoms of stroke-like episodes in MELAS. Neurology. 2005;64:710–2.PubMedCrossRefGoogle Scholar
  238. 238.
    Koga Y, Povalko N, Nishioka J, et al. MELAS and L-arginine therapy: pathophysiology of stroke-like episodes. Ann NY Acad Sci. 2010;1201:104–10.PubMedCrossRefGoogle Scholar
  239. 239.
    Kohan R, Cismondi IA, Oller-Ramirez N, et al. Therapeutic approaches to the challenge of neuronal ceroid lipofuscinoses. Curr Pharm Biotechnol. 2011;12:867–83.PubMedPubMedCentralCrossRefGoogle Scholar
  240. 240.
    Kohlschütter A, Schulz A. Toward understanding the neuronal ceroid lipofuscinosis. Brain & Devel. 2009;31:499–502.Google Scholar
  241. 241.
    Kotagal S, Geller TJ, Wall D, Lastra C. A child with reading impairment and a family history of adrenoleukodystrophy. Semin Pediatr Neurol. 1999;6:233–6.PubMedCrossRefGoogle Scholar
  242. 242.
    Kousi M, Siintola E, Dvorakova L, et al. Mutations in CLN7/MFSD8 are a common cause of variant late-infantile neuronal ceroid lipofuscinosis. Brain. 2009;132:810–9.PubMedCrossRefGoogle Scholar
  243. 243.
    Krabbe K. A new familial, infantile form of diffuse brain-sclerosis. Brain. 1916;39:73–114.CrossRefGoogle Scholar
  244. 244.
    Krasnewich D, Gahl WA. Carbohydrate-deficient glycoprotein syndrome. Adv Pediatr. 1997;44:109–40.PubMedGoogle Scholar
  245. 245.
    Kruer MC, Boddaert N. Neurodegeneration with brain iron accumulation: a diagnostic algorithm. Semin Pediatr Neurol. 2012;19:67–74.PubMedPubMedCentralCrossRefGoogle Scholar
  246. 246.
    Kumar AJ, Rosenbaum AE, Naidu S, et al. Adrenoleukodystrophy: correlating MR imaging with CT. Radiology. 1987;165:497–504.PubMedCrossRefGoogle Scholar
  247. 247.
    Kurian MA, McNeill A, Lin J-P, Maher ER. Childhood disorders of neurodegeneration with brain iron accumulation (NBIA). Dev Med Child Neurol. 2011;53:394–404.PubMedCrossRefGoogle Scholar
  248. 248.
    Lackner KJ, Monge JC, Gregg RE, et al. Analysis of the apolipoprotein B gene and messenger ribonucleic acid in abetalipoproteinemia. J Clin Invest. 1986;78:1707–12.PubMedPubMedCentralCrossRefGoogle Scholar
  249. 249.
    Lagrue E, Barantin L, Sirinelli D, Castelnau P. Diagnosis of Sjögren-Larsson syndrome by magnetic resonance spectroscopy. Pediatr Neurol. 2012;46:57–9.PubMedCrossRefGoogle Scholar
  250. 250.
    Landers III MB, Klintworth GK. Subacute sclerosing panencephalitis (SSPE). A clinicopathologic study of the retinal lesions. Arch Ophthalmol. 1971;86:156–63.PubMedCrossRefGoogle Scholar
  251. 251.
    Leavitt JA, Kotagal S. The “cherry red” spot. Pediatr Neurol. 2007;37:74–5.PubMedCrossRefGoogle Scholar
  252. 252.
    Leavitt JA, Singer W, Brown WL. Retinal and pontine striations in autosomal recessive spastic ataxia of Charlevoix-Saguenay. J Neuroophthalmol. 2014;34:369–71.PubMedCrossRefGoogle Scholar
  253. 253.
    Leboulch P. Gene therapy: primed for take off. Nature. 2014;500:280–2.CrossRefGoogle Scholar
  254. 254.
    Lee C, Dineen TE, Brack M, et al. The mucopolysaccharidoses: characterization by cranial MR imaging. AJNR Am J Neuroradiol. 1993;14:1285–92.PubMedGoogle Scholar
  255. 255.
    Lee MS, Kim YD, Lyoo CH. Oculogyric crisis as an initial manifestation of Wilson’s disease. Neurology. 1999;52:1714–5.PubMedCrossRefGoogle Scholar
  256. 256.
    Lee AG, Olson RJ, Bonthius DJ, Phillips PH. Increasing exotropia and decreasing vision in a school-aged boy. Surv Ophthalmol. 2007;52:672–9.PubMedCrossRefGoogle Scholar
  257. 257.
    Lee R, Apkarian K, Jung ES, et al. Corpus callosum diffusion tensor imaging and volume measures are associated with disease severity in pediatric Niemann-Pick disease type C1. Pediatr Neurol. 2014;51:669–74.PubMedPubMedCentralCrossRefGoogle Scholar
  258. 258.
    Leigh RJ, Zee DS. The neurology of eye movements: contemporary neurology series, vol. 4. 2nd ed. Philadelphia: Oxford University Press; 2006. p. 680.Google Scholar
  259. 259.
    Lennox G, Jones R. Gaze distractibility in Wilson’s disease. Ann Neurol. 1989;25:415–7.PubMedCrossRefGoogle Scholar
  260. 260.
    Leone P, Janson CG, Bilanuk L. Aspartoacylase gene transfer to the central nervous system with therapeutical implications for Canavan disease. Ann Neurol. 2000;48:27–38.PubMedCrossRefGoogle Scholar
  261. 261.
    Lerman-Sagie T, Leshinsky-Silver E, Watemberg N, et al. White matter involvement in mitochondrial diseases. Mol Genet Metab. 2005;48:16–23.Google Scholar
  262. 262.
    Levin PS, Green WR, Victor DI, et al. Histopathology of the eye in Cockayne’s syndrome. Arch Ophthalmol. 1983;101:1093–7.PubMedCrossRefGoogle Scholar
  263. 263.
    Li Y, Sands MS. Experimental therapies in the murine model of globoid cell leukodystrophy. Pediatr Neurol. 2014;51:600–6.PubMedPubMedCentralCrossRefGoogle Scholar
  264. 264.
    Libert J, Van Hoof F, Toussaint D, et al. Ocular findings in metachromatic leukodystrophy. Arch Ophthalmol. 1979;97:1495–504.PubMedCrossRefGoogle Scholar
  265. 265.
    Lowden JA. Evidence for a hybrid hexosaminidase isoenzyme and heterozygotes for Sandhoff disease. Am J Hum Genet. 1979;31:281–9.PubMedPubMedCentralGoogle Scholar
  266. 266.
    Lyon G, Adams RD, Kolodny EH. Neurology of hereditary metabolic diseases in children. 2nd ed. New York: McGraw-Hill; 1996.Google Scholar
  267. 267.
    Lyons CJ, Castano G, McCormick AQ, Applegarth D. Leopard spot retinal pigmentation in infancy indicating a peroxisomal disorder. Br J Ophthalmol. 2004;88:191–2.PubMedPubMedCentralCrossRefGoogle Scholar
  268. 268.
    Lysosomal storage disorders: pharmacological chaperones and mechanism of action. Amicus Therapeutics Web site. Accessed 9 Jul 2008.
  269. 269.
    MacDonald JT, Sher PK. Ophthalmoplegia as a sign of metabolic disease in the newborn. Neurology. 1977;27:971–3.PubMedCrossRefGoogle Scholar
  270. 270.
    MacFaul R, Cavanagh N, Lake BD, et al. Metachromatic leukodystrophy: review of 38 cases. Arch Dis Child. 1982;57:168–75.PubMedPubMedCentralCrossRefGoogle Scholar
  271. 271.
    Machara M, Ogasawara N, Mizutani N, et al. Cytochrome c oxidase deficiency in Menkes kinky hair disease. Brain Dev. 1983;5:533–40.CrossRefGoogle Scholar
  272. 272.
    Macmillan CJ, Shoubridge EA. Mitochondrial DNA depletion: prevalence in a pediatric population referred for neurologic evaluation. Pediatr Neurol. 1996;14:203–10.PubMedCrossRefGoogle Scholar
  273. 273.
    Madhavarao CN, Arun P, Moffett JR, et al. Defective N-acetylaspartate catabolism reduces brain acetate levels and myelin lipid synthesis in Canavan’s disease. Proc Natl Acad Sci U S A. 2005;102:5221–6.PubMedPubMedCentralCrossRefGoogle Scholar
  274. 274.
    Maegawa GHB, Banwell BL, Blaser S, et al. Substrate reduction therapy in juvenile GM2 gangliosidosis. Mol Genet Metab. 2009;98:215–24.PubMedCrossRefGoogle Scholar
  275. 275.
    Magalhaes AC, Caramelli P, Menezes JR, et al. Wilson’s disease: MRI with clinical correlation. Neuroradiology. 1994;36:97–100.PubMedCrossRefGoogle Scholar
  276. 276.
    Mahajnah M, Zelnik N. Phenotypic heterogeneity in consanguineous patients with a common CLN8 mutation. Pediatr Neurol. 2012;47:303–5.PubMedCrossRefGoogle Scholar
  277. 277.
    Mallery DL, Tanganelli B, Colella S, et al. Molecular analysis of mutations in the CSB (ERCC6) gene in patients with Cockayne syndrome. Am J Hum Genet. 1998;62:77–85.PubMedPubMedCentralCrossRefGoogle Scholar
  278. 278.
    Mano T, Ono J, Kaminaga T, et al. Proton MR spectroscopy of Sjögren-Larsson’s syndrome. AJNR AM J Neuroradiol. 1999;20:1671–3.PubMedGoogle Scholar
  279. 279.
    Marble M, Voeller KS, May MM. Pelizaeus-Merzbacher syndrome: neurocognitive function in a family with carrier manifestations. Am J Med Genet. 2007;143A(13):1442–7.PubMedCrossRefGoogle Scholar
  280. 280.
    Markesbery WR, Shield LK, Egel RT, et al. Late infantile neuronal ceroid-lipofuscinosis: an ultrastructural study of lymphocyte inclusions. Arch Neurol. 1976;33:630–5.PubMedCrossRefGoogle Scholar
  281. 281.
    Martin M-H, Bochard J-P, Sylvain M, et al. Autosomal recessive spastic ataxia of Charlevoix-Saguenay: a report of MR imaging in 5 patients. AJNR Am J Neuroradiol. 2007;28:1606–8.PubMedCrossRefGoogle Scholar
  282. 282.
    Matalon R, Matalon R. Canavan disease. In: Raymond G, Eichler F, Fatemi A, Naidu S, editors. Leukodystrophies. London: Mac Keith Press; 2011. p. 156–9.Google Scholar
  283. 283.
    Matalon R, Michals K, Sebesta D, et al. Aspartoacylase deficiency and N-acetylaspartic aciduria in patients with Canavan disease. Am J Med Genet. 1988;29:463–71.PubMedCrossRefGoogle Scholar
  284. 284.
    Matalon R, Michals-Matalon K. Biochemistry and molecular biology of Canavan disease. Neurochem Res. 1999;24:507–13.PubMedCrossRefGoogle Scholar
  285. 285.
    Matsuo M. Challenges of supplementary treatment for neurodegenerative diseases. Brain Dev. 2012;34:85–6.PubMedCrossRefGoogle Scholar
  286. 286.
    Matthews PM, Tampieri D, Berkovic SF, et al. Magnetic resonance imaging shows specific abnormalities in the MELAS syndrome. Neurology. 1991;41:1043–6.PubMedCrossRefGoogle Scholar
  287. 287.
    McGovern MM, Wasserstein MP, Aron A. Ocular manifestations of Niemann-Pick disease type B. Ophthalmology. 2004;111:1424–7.PubMedCrossRefGoogle Scholar
  288. 288.
    McGuinness MC, Wei H, Smith KD. Therapeutic developments in peroxisome biogenesis disorders. Expert Opin Investig Drugs. 2000;9:1985–92.PubMedCrossRefGoogle Scholar
  289. 289.
    McKinney AM, Nascene D, Miller WP, et al. Childhood cerebral X-linked adrenoleukodystrophy: diffusion tensor imaging measurements for prediction of clinical outcome after hematopoietic stem cell transplantation. AJNR Am J Neuroradiol. 2013;34:641–9.PubMedCrossRefGoogle Scholar
  290. 290.
    Medina L, Chi TL, DeVivo DC. MR findings in patients with subacute necrotizing encephalomyelopathy (Leigh syndrome): correlation with biochemical defect. AJNR Am J Neuroradiol. 1990;11:379–84.PubMedGoogle Scholar
  291. 291.
    Menkes JH, Alter M, Steigleder GK, et al. A sex-linked recessive disorder with retardation of growth, peculiar hair, and focal cerebral and cerebellar degeneration. Pediatrics. 1962;29:764–9.PubMedGoogle Scholar
  292. 292.
    Messing A, Brenner M, Fenny MB, et al. Alexander disease. J Neurosci. 2012;32:5017–23.PubMedPubMedCentralCrossRefGoogle Scholar
  293. 293.
    Migeon BR, Moser HW, Moser AB, et al. Adrenoleukodystrophy: evidence for X linkage, inactivation and selection favoring the mutant allele in heterozygous cells. Proc Natl Acad Sci U S A. 1981;78:5066–70.PubMedPubMedCentralCrossRefGoogle Scholar
  294. 294.
    Migita M, Hamada H, Fujimura J, et al. Glucocerebrosidase level in the cerebrospinal fluid during enzyme replacement therapy—unsuccessful treatment of the neurologic abnormality in type 2 Gaucher disease. Eur J Pediatr. 2003;162:524–5.PubMedCrossRefGoogle Scholar
  295. 295.
    Milone M. Mitochondrial DNA, multiple deletion syndromes, autosomal dominant and recessive (POLG, POLG2, TWINKLE, and ANT1). In: Wong L-JC, editor. Mitochondrial disorders caused by nuclear genes. New York: Springer; 2014.Google Scholar
  296. 296.
    Milone M, Benarroch EE, Wong L-J. POLG-related disorders: defects of the nuclear and mitochondrial genome interaction. Neurology. 2011;77:1847–52.PubMedCrossRefGoogle Scholar
  297. 297.
    Milone M, Wong L-J. Diagnosis of mitochondrial myopathies. Mol Genet Metab. 2013;110:35–41.PubMedCrossRefGoogle Scholar
  298. 298.
    Moghadasian MH, Salen G, Frohlich JJ, et al. Cerebrotendinous xanthomatosis: a rare disease with diverse manifestations. Arch Neurol. 2002;59:527–9.PubMedCrossRefGoogle Scholar
  299. 299.
    Mole SE. The neuronal ceroid lipofuscinosis (NCL): a group of lysosomal diseases come of age. Brain Pathol. 2004;14:70–6.PubMedCrossRefGoogle Scholar
  300. 300.
    Moloney JB, Masterson JG. Detection of adrenoleukodystrophy carriers by means of evoked potentials. Lancet. 1982;2:852–3.PubMedCrossRefGoogle Scholar
  301. 301.
    Moossy J. The neuropathology of Cockayne’s syndrome. J Neuropathol Exp Neurol. 1967;26:654–60.PubMedCrossRefGoogle Scholar
  302. 302.
    Morales CT, Shanske S, Tritschler HJ, et al. MtDNA depletion with variable tissue expression: a novel genetic abnormality in mitochondrial disease. Am J Hum Genet. 1991;48:492–501.Google Scholar
  303. 303.
    Morava E, Wosik HN, Sykut-Cegielska J, et al. Ophthalmological abnormalities in children with congenital disorders of glycosylation type 1. Br J Ophthalmol. 2009;93:350–4.PubMedCrossRefGoogle Scholar
  304. 304.
    Moroni I, Bugiani M, Bizzi A, et al. Cerebral white matter involvement in children with mitochondrial encephalopathies. Neuropediatrics. 2002;33:79–85.PubMedCrossRefGoogle Scholar
  305. 305.
    Moser HW. Adrenoleukodystrophy: phenotype, genetics, pathogenesis, and therapy. Brain. 1997;120:1485–508.PubMedCrossRefGoogle Scholar
  306. 306.
    Moser AB, Kreiter N, Bezman L, et al. Plasma very long chain fatty acids in 3,000 peroxisome disease patients and 29,000 controls. Ann Neurol. 1999;45:100–10.PubMedCrossRefGoogle Scholar
  307. 307.
    Moser HW, Mahmood A, Raymond GV. X-linked adrenoleukodystrophy. Nat Clin Pract Neurol. 2007;3:140–50.PubMedCrossRefGoogle Scholar
  308. 308.
    Moser HW, Raymond GV, Dubey P. Adrenoleukodystrophy: new approaches to a neurodegenerative disease. JAMA. 2005;294:3131–4.PubMedCrossRefGoogle Scholar
  309. 309.
    Moser HW, Raymond GV, Lu SE, et al. Follow up of 89 asymptomatic patients with adrenoleukodystrophy treated with Lorenzo’s oil. Arch Neurol. 2005;62:1073–80.PubMedCrossRefGoogle Scholar
  310. 310.
    Mudd SH, Skovby F, Levy HL, et al. The natural history of homocystinuria due to cystathionine beta-synthase deficiency. Am J Hum Genet. 1985;37:1–31.PubMedPubMedCentralGoogle Scholar
  311. 311.
    Muller DP. Effect of large oral doses of vitamin E on the neurological sequelae of patients with abetalipoproteinemia. In: Lubin B, Machlin LJ, editors. Vitamin E: biochemical, hematological and clinical aspects. New York: New York Academy of Sciences; 1992. p. 133–44.Google Scholar
  312. 312.
    Naidu S, Hofmann KJ, Moser HW, et al. Galactosylceramide-betagalactosidase deficiency in association with cherry red spot. Neuropediatrics. 1988;19:46–8.PubMedCrossRefGoogle Scholar
  313. 313.
    Naidu S, Moser H. Peroxisomal disorders. In: Swaiman KF, editor. Pediatric neurology. Principles and practice. 2nd ed. St. Louis: C.V. Mosby; 1994. p. 1357–83.Google Scholar
  314. 314.
    Nakagawa E, Hirano S, Yamauchi H, et al. Progressive brainstem and white matter lesions in Kearns-Sayre syndrome: a case report. Brain Dev. 1994;16:416–8.PubMedCrossRefGoogle Scholar
  315. 315.
    Nakaya-Onishi M, Suzuki A, Okamoto N, et al. Observations on time course changes of the cherry red spot in a patient with Tay-Sachs disease. Br J Ophthalmol. 2000;2000(84):1320–1.Google Scholar
  316. 316.
    Nance MA, Berry SA. Cockayne syndrome: review of 140 cases. Am J Med Genet. 1992;42:167–79.CrossRefGoogle Scholar
  317. 317.
    Naughten ER, Jenkins J, Francis DE, et al. Outcome of maple syrup urine disease. Arch Dis Child. 1982;57:918–21.PubMedPubMedCentralCrossRefGoogle Scholar
  318. 318.
    Naz H, Izlam A, Waheed A, et al. Human β-glucuronidase: structure, function, and application in enzyme replacement therapy. Rejuvenation Res. 2013;16:352–63.PubMedCrossRefGoogle Scholar
  319. 319.
    Neville BG, Lake BD, Stephens R, et al. A neurovisceral storage disease with vertical supranuclear ophthalmoplegia and its relationship to Niemann-Pick disease: a report of nine patients. Brain. 1973;96:97–120.PubMedCrossRefGoogle Scholar
  320. 320.
    Ni Q, Johns GS, Manepalli A, et al. Infantile Alexander’s disease: serial neuroradiologic findings. J Child Neurol. 2002;17:463–6.PubMedCrossRefGoogle Scholar
  321. 321.
    Nie SS, Chen G, Chow X, Zhang Y. Cerebrotendinous xanthomatosis: a comprehensive review of pathogenesis, clinical manifestations, diagnosis, and management. Orphenet J Rare Dis. 2014;9:179.CrossRefGoogle Scholar
  322. 322.
    Nowak VA, Bremner F, Massey L. Kjellin syndrome: hereditary spastic paraplegia with pathognomonic macular appearance. Pract Neurol. 2014;14:278–9.PubMedCrossRefGoogle Scholar
  323. 323.
    Oldfors A, Fyhr IM, Holme E, et al. Neuropathology in Kearns-Sayre syndrome. Acta Neuropathol. 1990;80:541–6.PubMedCrossRefGoogle Scholar
  324. 324.
    Orlin A, Sondhi D, Witmer MT, et al. Spectrum of ocular manifestations in CLN2-associated Batten (Jansky-Bielschowsky) disease correlate with advancing age and deteriorating neurological function. PLoS One. 2013;8:e73128.PubMedPubMedCentralCrossRefGoogle Scholar
  325. 325.
    Ortiz R, Newman NJ, Shoffner JM, et al. Variable retinal and neurological manifestations in patients harboring the mtDNA 8993 mutation. Arch Ophthalmol. 1993;111:1525–30.PubMedCrossRefGoogle Scholar
  326. 326.
    Ortube MC, Bhola R, Demer JL. Orbital magnetic resonance imaging of extraocular muscles in chronic progressive external ophthalmoplegia: specific diagnostic findings. J AAPOS. 2006;10:414–8.PubMedPubMedCentralCrossRefGoogle Scholar
  327. 327.
    Ospina LH, Lyons CJ, McCormick AQ. “Cherry-red spot” or “perifoveal white patch”? Can J Ophthalmol. 2005;40:609–10.PubMedCrossRefGoogle Scholar
  328. 328.
    Ozawa M, Nishino I, Horai S, et al. Myoclonus epilepsy associated with ragged-red fibers. A G-to-A mutation at nucleotide pair 8363 in mitochondrial tRNA(lys) in two families. Muscle Nerve. 1997;20:271–8.PubMedCrossRefGoogle Scholar
  329. 329.
    Pampiglione G, Harden A. So-called neuronal ceroid lipofuscinosis: neurophysiological studies in 60 children. J Neurol Neurosurg Psychiatry. 1977;40:323–30.PubMedPubMedCentralCrossRefGoogle Scholar
  330. 330.
    Pampiglione G, Privett G, Harden A. Tay-Sachs disease: neurophysiological studies in 20 children. Dev Med Child Neurol. 1974;16:201–8.PubMedCrossRefGoogle Scholar
  331. 331.
    Patel B, Gimi B, Vachha B, et al. Optic nerve and chiasm enlargement in a case of infantile Krabbe disease: quantitative comparison with 26 age-matched controls. Pediatr Radiol. 2008;38:697–8.PubMedCrossRefGoogle Scholar
  332. 332.
    Patino LC, Battu R, Ortega-Recalde O, et al. Exome sequencing is an efficient tool for variant late infantile neuronal ceroid lipofuscinosis. PLoS One. 2014;9(10):e109576. doi: 10.1371/journal.pone.0109576.PubMedPubMedCentralCrossRefGoogle Scholar
  333. 333.
    Patterson MC, Di Bisceglie AM, Higgens JJ, et al. The effect of cholesterol-lowering agents on hepatic and plasma cholesterol in Niemann-Pick disease type C. Neurology. 1993;43:61–4.Google Scholar
  334. 334.
    Patterson MC, Horowitz M, Abel RB, et al. Isolated horizontal supranuclear gaze palsy as a marker of severe systemic involvement in Gaucher’s disease. Neurology. 1993;43:1993–7.PubMedCrossRefGoogle Scholar
  335. 335.
    Patterson MC, Vecchio D, Prady H, et al. Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study. Lancet Neurol. 2007;6:765–72.PubMedCrossRefGoogle Scholar
  336. 336.
    Peachey NS, Sokol S, Moskowitz A. Recording the contralateral PERG: effect of different electrodes. Invest Ophthalmol Vis Sci. 1983;24:1514–6.PubMedGoogle Scholar
  337. 337.
    Pearce JM. Canavan’s disease. J Neurol Neurosurg Psychiatry. 2004;75:1410.PubMedPubMedCentralCrossRefGoogle Scholar
  338. 338.
    Percy AK, Brady RO. Metachromatic leukodystrophy: diagnosis with samples of venous blood. Science. 1968;161:594–5.PubMedCrossRefGoogle Scholar
  339. 339.
    Persaud-Sawin DA, Mousallem T, Wang C, et al. Neuronal ceroid lipofuscinosis: a common pathway? Pediatr Res. 2007;61:146–52.PubMedCrossRefGoogle Scholar
  340. 340.
    Peters C, Charnas LR, Tan Y, et al. Cerebral X-linked adrenoleukodystrophy: the international hematopoietic cell transplantation experience from 1982 to 1999. Blood. 2004;104:881–8.PubMedCrossRefGoogle Scholar
  341. 341.
    Petrohelos M, Tricoulis D, Kotsiras I, Vouzoukos A. Ocular manifestations of Gaucher’s disease. Am J Ophthalmol. 1975;80:1006–10.PubMedCrossRefGoogle Scholar
  342. 342.
    Pitz S, Ogun O, Bajbouj M, et al. Ocular changes in patients with mucopolysaccharidosis 1 receiving enzyme replacement therapy: a 4-year experience. Arch Ophthalmol. 2007;125:1353–6.PubMedCrossRefGoogle Scholar
  343. 343.
    Plant GT, Hess RF. The electrophysiological assessment of optic neuritis. In: Hess RF, Plant GT, editors. Optic neuritis. Cambridge: Cambridge University Press; 1986. p. 208–14.Google Scholar
  344. 344.
    Poll-The BT, Engelen M. Peroxisomal leukoencephalopathy. Semin Neurol. 2015;32:42–6.Google Scholar
  345. 345.
    Poll-The BT, Gärtner J. Clinical diagnosis, biochemical findings and MRI spectrum of peroxisomal disorders. Biochim Biophys Acta. 1822;2012:1421–9.Google Scholar
  346. 346.
    Poll-The BT, de Buy M, Wenniger-Prick LJ, Barth PG, et al. The eye as a window to inborn errors of metabolism. J Inherit Metab Dis. 2003;26:229–44.PubMedCrossRefGoogle Scholar
  347. 347.
    Pontikis CC, Cella CV, Parihar N, et al. Late-onset neurodegeneration in the cln3-/-mouse model of juvenile neuronal ceroid lipofuscinosis is preceded by low level glial activation. Brain Res. 2004;1023:231–42.PubMedCrossRefGoogle Scholar
  348. 348.
    Porter-Grenn L, Silbergleit R, Mehta BA. Hallervorden-Spatz disease with bilateral involvement of globus pallidus and substantia nigra: MR demonstration. J Comput Assist Tomogr. 1993;17:961–3.PubMedCrossRefGoogle Scholar
  349. 349.
    Pouwels PJW, Vanderver A, Bernard G, et al. Hypomyelinating leukodystrophies: translational research progress and prospects. Ann Neurol. 2014;76:5–19.PubMedCrossRefGoogle Scholar
  350. 350.
    Prall FR, Drack A, Taylor M, et al. Ophthalmic manifestations of Danon disease. Ophthalmology. 2006;113:1010–3.PubMedCrossRefGoogle Scholar
  351. 351.
    Pridmore CL, Baraitser M, Harding B, et al. Alexander’s disease: clues to diagnosis. J Child Neurol. 1993;8:134–44.PubMedCrossRefGoogle Scholar
  352. 352.
    Puech B, Lacour A, Stavenin G, et al. Kjellin syndrome: long term neuro-ophthalmologic follow-up, and novel mutations in the SPG11 gene. Ophthalmology. 2011;118:564–73.PubMedCrossRefGoogle Scholar
  353. 353.
    Rader DJ, Brewer Jr HB. Abetalipoproteinemia. New insights into lipoprotein assembly and vitamin E metabolism from a rare genetic disease. JAMA. 1993;270:865–9.PubMedCrossRefGoogle Scholar
  354. 354.
    Rahman S, Blok RB, Dahl HH, et al. Leigh syndrome: clinical features and biochemical and DHA abnormalities. Ann Neurol. 1996;39:343–51.PubMedCrossRefGoogle Scholar
  355. 355.
    Raininko R, Santavuori P, Heiskala H, et al. CT findings in neuronal ceroid lipofuscinosis. Neuropediatrics. 1990;21:95–101.PubMedCrossRefGoogle Scholar
  356. 356.
    Rapin I, Weidenheim K, Lindenbaum Y, et al. Cockayne syndrome in adults: review with clinical and pathological study of a new case. J Child Neurol. 2006;21:991–1006.PubMedPubMedCentralCrossRefGoogle Scholar
  357. 357.
    Reichard EA, Ball Jr WS, Bove KE. Alexander disease: a case report and review of the literature. Pediatr Pathol Lab Med. 1996;16:327–43.PubMedCrossRefGoogle Scholar
  358. 358.
    Reider-Grosswasser I, Bornstein N. CT and MRI in late-onset metachromatic leukodystrophy. Acta Neurol Scand. 1987;75:64–9.PubMedCrossRefGoogle Scholar
  359. 359.
    Renaud D. Clinical approach to leukoencephalopathies. Semin Neurol. 2012;32:29–33.PubMedCrossRefGoogle Scholar
  360. 360.
    Renaud DL. Leukoencephalopathy associated with macrocephaly. Semin Neurol. 2012;32:34–41.PubMedCrossRefGoogle Scholar
  361. 361.
    Renaud DL. Lysosomal disorders associated with leukoencephalopathy. Semin Neurol. 2012;32:51–4.PubMedCrossRefGoogle Scholar
  362. 362.
    Renaud DL, Kotagal S. Pantothenate-kinase associated neurodegeneration (PKAN) “eye of the tiger” sign. Pediatr Neurol. 2007;36:70–1.PubMedCrossRefGoogle Scholar
  363. 363.
    Renaud DR, Brodsky MC. GM2-gangliosidosis, AB variant: clinical, ophthalmological, MRI, and molecular findings. JIMD Rep. 2015.Google Scholar
  364. 364.
    Renteria VG, Ferrans VJ, Roberts WC. The heart in the Hurler syndrome: gross histologic and ultrastructural observations in five necropsy cases. Am J Cardiol. 1976;38:487–501.PubMedCrossRefGoogle Scholar
  365. 365.
    Resnick JS, Engel WK, Sever JL. Subacute sclerosing panencephalitis. Spontaneous improvement in a patient with elevated measles antibody in blood and spinal fluid. N Engl J Med. 1968;279:126–9.PubMedCrossRefGoogle Scholar
  366. 366.
    Risk WS, Haddad FS, Chemali R. Substantial spontaneous long-term improvement in subacute sclerosing panencephalitis. Six cases from the Middle East and a review of the literature. Arch Neurol. 1978;35:494–502.PubMedCrossRefGoogle Scholar
  367. 367.
    Rizzo WB, Jenkens SM, Boucher P. Recognition and diagnosis of neuro-ichthyotic syndromes. Semin Neurol. 2012;32:75–84.PubMedCrossRefGoogle Scholar
  368. 368.
    Robb RM, Watters GV. Ophthalmic manifestations of subacute sclerosing panencephalitis. Arch Ophthalmol. 1970;83:426–35.PubMedCrossRefGoogle Scholar
  369. 369.
    Robertson Jr WC, Clark DB, Markesbery WR. Review of 38 cases of subacute sclerosing panencephalitis: effect of amantadine on the natural course of the disease. Ann Neurol. 1980;8:422–5.PubMedCrossRefGoogle Scholar
  370. 370.
    Roh JK, Lee TG, Wie BA, et al. Initial and follow-up brain MRI findings and correlation with the clinical course in Wilson disease. Neurology. 1994;44:1064–8.PubMedCrossRefGoogle Scholar
  371. 371.
    Roos JCP, Lachmann RH, Carpenter RH, Cox TM. Latency vs. saccadic parameters in lysosomal trials. Ophthalmology. 2011;118:794.PubMedCrossRefGoogle Scholar
  372. 372.
    Röttach KG, von Maydell RD, Das VE, et al. Evidence for independent feedback control of horizontal and vertical saccades from Niemann-Pick type C disease. Vision Res. 1997;37:3627–38.PubMedCrossRefGoogle Scholar
  373. 373.
    Royce PM, Camakaris J, Danks DM. Reduced lysyl oxidase activity in skin fibroblasts from patients with Menkes’ kinky hair disease. Biochem J. 1980;192:579–82.PubMedPubMedCentralCrossRefGoogle Scholar
  374. 374.
    Rucker JC, Shapiro BE, Han YH, et al. Neuro-ophthalmology of late-onset Tay-Sachs disease (LOTS). Neurology. 2004;63:1918–26.PubMedCrossRefGoogle Scholar
  375. 375.
    Rudich DS, Curcio CA, Wasserstein M, Brodie SE. Inner macular hyperreflectivity demonstrated by optical coherence tomography in Niemann-Pick disease. JAMA Ophthalmol. 2013;131:1244–6.PubMedPubMedCentralCrossRefGoogle Scholar
  376. 376.
    Runge P, Muller DP, McAllister J, et al. Oral vitamin E supplements can prevent the retinopathy of abetalipoproteinemia. Br J Ophthalmol. 1986;70:166–73.PubMedPubMedCentralCrossRefGoogle Scholar
  377. 377.
    Russo Jr LS, Aron A, Anderson PJ. Alexander’s disease. A report and reappraisal. Neurology. 1976;26:607–14.PubMedCrossRefGoogle Scholar
  378. 378.
    Saatci I, Topcu M, Balaoglu FF, et al. Cranial MR findings in Wilson disease. Acta Radiol. 1997;38:250–8.PubMedCrossRefGoogle Scholar
  379. 379.
    Sahin M. Gene therapy for neurodegenerative disease. Pediatr Neurol. 2014;51:595–6.PubMedCrossRefGoogle Scholar
  380. 380.
    Salmon JF, Pan EL, Murray AD. Visual loss with dancing extremities and mental disturbances. Surv Ophthalmol. 1991;35:299–306.PubMedCrossRefGoogle Scholar
  381. 381.
    Salt HB, Wolff OH, Lloyd JK, et al. On having no beta-lipoprotein: a syndrome comprising abeta lipoprotein, acanthocytosis, and steatorrhoea. Lancet. 1960;2:325–9.PubMedCrossRefGoogle Scholar
  382. 382.
    Santavuori P, Haltia M, Rapola J, et al. Infantile type of so-called neuronal ceroid lipofuscinosis. 1: a clinical study of 15 patients. J Neurol Sci. 1973;18:257–67.PubMedCrossRefGoogle Scholar
  383. 383.
    Santos MJ, Imanaka T, Shio H, et al. Peroxisomal membrane ghosts in Zellweger syndrome—aberrant organelle assembly. Science. 1988;239:1536–8.PubMedCrossRefGoogle Scholar
  384. 384.
    Schaumberg HH, Powers JM, Raine CS, et al. Adrenoleukodystrophy: a clinical and pathological study of 17 cases. Arch Neurol. 1975;32:577–91.CrossRefGoogle Scholar
  385. 385.
    Scheffer IE, Baraitser M, Wilson J, et al. Pelizaeus Merzbacher disease: classical or connatal? Neuropediatrics. 1991;22:71–8.PubMedCrossRefGoogle Scholar
  386. 386.
    Schiffmann R, Moller JR, Trapp BD, et al. Childhood ataxia with diffuse central nervous system hypomyelination. Ann Neurol. 1994;35:331–40.PubMedCrossRefGoogle Scholar
  387. 387.
    Schiffmann R, van der Knaap MS. An MRI-based approach to the diagnosis of white matter disorders. Neurology. 2009;72:750–9.PubMedPubMedCentralCrossRefGoogle Scholar
  388. 388.
    Schroder M, Schnabel D, Hurwitz R, et al. Molecular genetics of GM2-gangliosidosis AB variant: a novel mutation and expression in BHK cells. Hum Genet. 1993;92:437–40.PubMedCrossRefGoogle Scholar
  389. 389.
    Schutgens RB, Heymans HS, Wanders RJ, et al. Peroxisomal disorders: a newly recognized group of genetic diseases. Eur J Pediatr. 1986;144:430–40.PubMedCrossRefGoogle Scholar
  390. 390.
    Schwartz JF, Kolendrianos ET. Maple syrup urine disease. A review with a report of an additional case. Dev Med Child Neurol. 1969;11:460–70.PubMedCrossRefGoogle Scholar
  391. 391.
    Sedwick LA, Burde RM, Hodges III FJ. Leigh’s subacute necrotizing encephalomyelopathy manifesting as spasmus nutans. Arch Ophthalmol. 1984;102:1046–8.PubMedCrossRefGoogle Scholar
  392. 392.
    Seidova SF, Kotliar K, Foerger F, et al. Functional retinal changes in Gaucher disease. Doc Ophthalmol. 2009;118:151–4.PubMedCrossRefGoogle Scholar
  393. 393.
    Seil FJ, Schochet SS, Earle KM. Alexander’s disease in an adult. Report of a case. Arch Neurol. 1968;19:494–502.PubMedCrossRefGoogle Scholar
  394. 394.
    Seitelberger F. Pelizaeus Merzbacher disease. In: Viken P, Bruyn G, editors. Handbook of clinical neurology. Amsterdam: Elsevier; 1970. p. 150–202.Google Scholar
  395. 395.
    Seitz D, Grodd W, Schwab A, et al. MR imaging and localized proton MR spectroscopy in late infantile neuronal ceroid lipofuscinosis. AJNR Am J Neuroradiol. 1998;19:1373–7.PubMedGoogle Scholar
  396. 396.
    Sethi KD, Adams RJ, Loring DW, et al. Hallervorden-Spatz syndrome: clinical and magnetic resonance imaging correlations. Ann Neurol. 1988;24:692–4.PubMedCrossRefGoogle Scholar
  397. 397.
    Shah S, Ghosh S, Nagarajan L. Leukodystrophy: when gallbladder offers a clue to diagnosis. Pediatr Neurol. 2013;49:68–9.PubMedCrossRefGoogle Scholar
  398. 398.
    Shapira Y, Harel S, Russell A. Mitochondrial encephalomyopathies: a group of neuromuscular disorders with defects in oxidative metabolism. Isr J Med Sci. 1977;13:161–4.PubMedGoogle Scholar
  399. 399.
    Sharma SN, Sankhyan N, Kaira V, Garg A. Thalamic changes in Tay-Sachs’ disease. Arch Neurol. 2008;65:1669.PubMedCrossRefGoogle Scholar
  400. 400.
    Shimomura C, Matsui A, Choh H, et al. Magnetic resonance imaging in Pelizaeus Merzbacher disease. Pediatr Neurol. 1988;4:124–5.PubMedCrossRefGoogle Scholar
  401. 401.
    Shimozawa T, Tsukamoto Y, Suzuki T, et al. A human gene responsible for Zellweger syndrome that affects peroxisomal assembly. Science. 1992;255:1132–4.PubMedCrossRefGoogle Scholar
  402. 402.
    Shultz A, Kohlschutter A, Mink M, et al. NCL diseases: clinical perspectives. Biochim Biophys Acta. 1832;2013:1801–6.Google Scholar
  403. 403.
    Sijens PE, Westerlann HE, de Groot JC, et al. MR spectroscopy and diffusion tensor imaging of the brain in Sjögren-Larsson syndrome. Mol Genet Metab. 2009;98:367–71.PubMedCrossRefGoogle Scholar
  404. 404.
    Simons S, Wolf NI, McNeil N, et al. A de novo mutation in the β-tubulin gene TUBB4A results in the leukoencephalopathy hypomyelination with atrophy of the basal ganglia and cerebellum. Am J Hum Genet. 2013;92:767–73.PubMedPubMedCentralCrossRefGoogle Scholar
  405. 405.
    Singh I, Moser AE, Moser HW, et al. Adrenoleukodystrophy: Impaired oxidation of very long chain fatty acids in white blood cells, cultured skin fibroblasts, and amniocytes. Pediatr Res. 1984;18:286–90.PubMedCrossRefGoogle Scholar
  406. 406.
    Sistermans EA, de Coo RF, de Wijs IJ, et al. Duplication of the proteolipid protein gene is the major cause of Pelizaeus-Merzbacher disease. Neurology. 1998;50:1749–54.PubMedCrossRefGoogle Scholar
  407. 407.
    Sjögren T, Larsson T. Oligophrenia in combination with congenital ichthyosis and spastic disorders: a clinical and genetic study. Acta Psychiatr Neurol Scand Suppl. 1957;113:1–112.PubMedGoogle Scholar
  408. 408.
    Sokol RJ. Vitamin E, and neurologic deficits. Adv Pediatr. 1990;37:119–48.PubMedGoogle Scholar
  409. 409.
    Solders M, Martin DA, Andersson C, et al. Hematopoietic SCT: a useful treatment for late metachromatic leukodystrophy. Bone Marrow Transplant. 2014;49:1046–51.PubMedCrossRefGoogle Scholar
  410. 410.
    Solomon D, Winkelman AC, Zee DS, et al. Niemann-Pick type C disease in two affected sisters: ocular motor recordings and brainstem neuropathology. Ann NY Acad Sci. 2005;1039:436–45.PubMedCrossRefGoogle Scholar
  411. 411.
    Souillet G, Guffon N, Maire I, et al. Outcome of 27 patients with Hurler’s syndrome transplanted from either related or unrelated haematopoietic stem cell sources. Bone Marrow Transplant. 2003;31:1005–117.CrossRefGoogle Scholar
  412. 412.
    Spalton DJ, Taylor DS, Sanders MD. Juvenile Batten’s disease: an ophthalmological assessment of 26 patients. Br J Ophthalmol. 1980;64:726–32.PubMedPubMedCentralCrossRefGoogle Scholar
  413. 413.
    Stark KL, Gibson JB, Hertle RW, et al. Ocular motor signs in an infant with carbohydrate-deficient glycoprotein syndrome Type 1a. Am J Ophthalmol. 2000;130:533–5.PubMedCrossRefGoogle Scholar
  414. 414.
    Statz A, Boltshauser E, Schinzel A, et al. Computed tomography in Pelizaeus-Merzbacher disease. Neuroradiology. 1981;22:103–5.PubMedCrossRefGoogle Scholar
  415. 415.
    Stefanini M, Fawcett H, Botta E, et al. Genetic analysis of twenty two patients with Cockayne syndrome. Hum Genet. 1996;97:418–23.PubMedCrossRefGoogle Scholar
  416. 416.
    Steinberg SJ, Dodt G, Raymond GV, et al. Peroxisome biogenesis disorders. Biochim Biophys Acta. 1763;2006:1733–48.Google Scholar
  417. 417.
    Stem Cell Information. National Institutes of Health Web site. Accessed 9 Jul 2008.
  418. 418.
    Steriade C, Andrade DM, Faghfoury H, et al. Mitochondrial encephalopathy with lactic acidosis and stroke-like episodes (MELAS) may respond to adjunctive ketogenic diet. Pediatr Neurol. 2014;50:498–502.PubMedCrossRefGoogle Scholar
  419. 419.
    Stevanin G, Montagna G, Azzedine H, et al. Mutations in SPG11 are frequent in autosomal recessive spastic paraplegia with thin corpus callosum, cognitive decline and lower motor neuron degeneration. Brain. 2008;131:772–84.PubMedCrossRefGoogle Scholar
  420. 420.
    Stevenson RE, Schroer RJ, Schwartz CE. Pelizaeus-Merzbacher syndrome. X-linked mental retardation. New York: Oxford University Press; 2000. p. 266–8.Google Scholar
  421. 421.
    Stewart JD, Tennant S, Powell H, et al. Novel POLG1 mutations associated with neuromuscular and liver phenotypes in adults and children. J Med Genet. 2009;46:209–14.PubMedCrossRefGoogle Scholar
  422. 422.
    Stockler S, Millner M, Molzer B, et al. Multiple sclerosis-like syndrome in a woman heterozygous for adrenoleukodystrophy. Eur Neurol. 1993;33:390–2.PubMedCrossRefGoogle Scholar
  423. 423.
    Stone DL, Tayebi N, Orvisky E, et al. Glucocerebrosidase gene mutations in patients with type 2 Gaucher disease. Hum Mutat. 2000;15:181–8.PubMedCrossRefGoogle Scholar
  424. 424.
    Summers CG, Purple RL. Krivit WL Ocular changes in the mucopolysaccharidoses post bone marrow transplantation. A preliminary report. Ophthalmology. 1989;96:977–84.PubMedCrossRefGoogle Scholar
  425. 425.
    Surendran S, Matalon KM, Tyring SK, et al. Molecular basis of Canavan’s disease: from human to mouse. J Child Neurol. 2003;18:604–10.PubMedCrossRefGoogle Scholar
  426. 426.
    Suzuki K. Biochemical pathogenesis of genetic leukodystrophies: comparison of metachromatic leukodystrophy and globoid cell leukodystrophy (Krabbe’s disease). Neuropediatrics. 1984;15:32–6.PubMedCrossRefGoogle Scholar
  427. 427.
    Svennerholm L. The gangliosides. J Lipid Res. 1964;5:145–55.PubMedGoogle Scholar
  428. 428.
    Svetl M, Kozić D, Stefanova E, et al. Dystonia in Wilson’s disease. Mov Disord. 2001;16:719–23.CrossRefGoogle Scholar
  429. 429.
    Swaiman KF. Hallervorden-Spatz syndrome in brain iron metabolism. Arch Neurol. 1991;48:1285–93.PubMedCrossRefGoogle Scholar
  430. 430.
    Swaiman KF. Lysosomal diseases. In: Swaiman KF, editor. Pediatric neurology, principles and practice, vol. 11. 2nd ed. St. Louis: C.V. Mosby; 1994. p. 1275–334.Google Scholar
  431. 431.
    Swaiman KF. Hallervorden-Spatz syndrome. Pediatr Neurol. 2001;25:102–8.PubMedCrossRefGoogle Scholar
  432. 432.
    Swaiman KF, Smith SA, Trock GL, et al. Sea-blue histiocytes, lymphocytic cytosomes, and 59Fe: studies in Hallervorden-Spatz syndrome. Neurology. 1983;33:301–5.PubMedCrossRefGoogle Scholar
  433. 433.
    Tang S, Wang J, Lee N-C, et al. Mitochondrial DNA polymerase γ mutations: an ever expanding molecular and clinical spectrum. J Med Genet. 2011;48:669–81.PubMedCrossRefGoogle Scholar
  434. 434.
    Tarugi P, Averna M, Di Leo E, et al. Molecular diagnosis of hypobetalipoproteinemia: an ENID review. Atherosclerosis. 2007;195:e19–27.PubMedCrossRefGoogle Scholar
  435. 435.
    Taylor D. Ophthalmological features of some human hereditary disorders with demyelination. Bull Soc Belge Ophthalmol. 1983;208:405–13.Google Scholar
  436. 436.
    Taylor D. Neurometabolic disease. Pediatric ophthalmology. London: Blackwell; 1990. p. 525–44.Google Scholar
  437. 437.
    Taylor RW, Pyle A, Griffin H, et al. Use of whole-exome sequencing to determine the genetic basis of multiple mitochondrial respiratory chain complex deficiencies. JAMA. 2014;312:68–77.PubMedCrossRefGoogle Scholar
  438. 438.
    Tesluk H, Munn RJ, Schwartz MZ, Ruebner BH. Papillomatous transformation of the gallbladder in metachromatic leukodystrophy. Pediatr Pathol. 1989;9(6):741–6.PubMedCrossRefGoogle Scholar
  439. 439.
    Traboulsi EI, Maumenee IH. Ophthalmologic manifestations of X-linked childhood adrenoleukodystrophy. Ophthalmology. 1987;94:47–52.PubMedCrossRefGoogle Scholar
  440. 440.
    Traverso M, Yuregir OO, Mimouni-Bloch A, et al. Hypomyelination and congenital cataract: identification of two novel mutations in two unrelated families. Eur J Paediatr Neurol. 2013;17:108–11.PubMedCrossRefGoogle Scholar
  441. 441.
    Tripp JH, Lake BD, Young E, et al. Juvenile Gaucher’s disease with horizontal gaze palsy in three siblings. J Neurol Neurosurg Psychiatry. 1977;40:470–8.PubMedPubMedCentralCrossRefGoogle Scholar
  442. 442.
    Trobe JD, Sharpe JA, Hirsh DK, et al. Nystagmus of Pelizaeus-Merzbacher disease: a magnetic search-coil study. Arch Neurol. 1991;48:87–91.PubMedCrossRefGoogle Scholar
  443. 443.
    Trocello JM, Guichard JP, Levendecker A. Corpus callosum abnormalities in Wilson’s disease. J Neurol Neurosurg Psychiatry. 2011;82:1119–21.PubMedCrossRefGoogle Scholar
  444. 444.
    Troelstra C, Landsvater RM, Weigant J, et al. Localization of the nucleotide excision repair gene ERCC6 to human chromosome 10q11-q21. Genomics. 1992;12:745–9.PubMedCrossRefGoogle Scholar
  445. 445.
    Troelstra C, van Gool A, deWit J, et al. ERCC6, a member of a subfamily of putative helicases, is involved in Cockayne’s syndrome and preferential repair of active genes. Cell. 1992;71:939–53.PubMedCrossRefGoogle Scholar
  446. 446.
    Tsina EK, Marsden DL, Hansen RM, et al. Maculopathy and retinal degeneration in cobalamin c methylmalonic aciduria and homocystinuria. Arch Ophthalmol. 2005;123:1143–5.PubMedCrossRefGoogle Scholar
  447. 447.
    Tulinius MH, Holme E, Kristiansson B, et al. Mitochondrial encephalomyelopathies in childhood. I. biochemical and morphologic investigations. J Pediatr. 1991;119:242–50.PubMedCrossRefGoogle Scholar
  448. 448.
    Tulinius MH, Holme E, Kristiansson B, et al. Mitochondrial encephalomyopathies in childhood. II. Clinical manifestations and syndromes. J Pediatr. 1991;119:251–9.PubMedCrossRefGoogle Scholar
  449. 449.
    Tümer Z. An overview and update of ATP7A mutations leading to Menkes disease and occipital horn syndrome. Hum Mutat. 2013;34:417–29.PubMedCrossRefGoogle Scholar
  450. 450.
    Tyler HR. Pelizaeus-Merzbacher disease. AMA Arch Neurol Psychiatry. 1958;80:162–9.PubMedCrossRefGoogle Scholar
  451. 451.
    Udow S, Bunge M, Ryner L, et al. Prolonged survival and serial magnetic resonance spectroscopy changes in infantile Krabbe disease. Pediatr Neurol. 2012;47:299–302.PubMedCrossRefGoogle Scholar
  452. 452.
    Vafai SB, Mootha VK. A common pathway for a rare disease. Science. 2013;342:1453–4.PubMedCrossRefGoogle Scholar
  453. 453.
    Valavanis A, Friede RL, Schubiger O, et al. Computed tomography in neuronal ceroid lipofuscinosis. Neuroradiology. 1980;19:35–8.PubMedGoogle Scholar
  454. 454.
    van der Knaap MS, Barth PG, Gabreëls FJ, et al. A new leukoencephalopathy with vanishing white matter. Neurology. 1997;48:845–55.PubMedCrossRefGoogle Scholar
  455. 455.
    van der Knapp MS, Barth PG, Stroink H, et al. Leukoencephalopathy with swelling and a discrepantly mild clinical course in eight children. Ann Neurol. 1995;37:324–34.CrossRefGoogle Scholar
  456. 456.
    van der Knapp MS, Breiter S, Naidu S, et al. Defining and categorizing leukoencephalopathies of unknown origin: MR imaging approach. Radiology. 1999;213:121–33.CrossRefGoogle Scholar
  457. 457.
    van der Knapp MS, Kamphorst W, Barth PG, et al. Phenotypic variation in leukoencephalopathy with vanishing white matter. Neurology. 1998;51:540–7.CrossRefGoogle Scholar
  458. 458.
    van der Knaap MS, Naidu S, Breiter SN, et al. Alexander disease: diagnosis with MR imaging. AJNR Am J Neuroradiol. 2001;22:541–52.PubMedGoogle Scholar
  459. 459.
    van der Knaap MS, Valk J. GM2 Gangliosidosis. In: van der Knaap MS, Valk J, editors. Magnetic resonance of myelination and myelin disorders. 3rd ed. Berlin: Springer; 2005. p. 103–11.CrossRefGoogle Scholar
  460. 460.
    Van der Knaap MS, Valk J. Magnetic resonance of myelin, myelination and myelin disorders. Heidelberg: Springer; 1995.CrossRefGoogle Scholar
  461. 461.
    van der Knapp MS, Valk J. The MR spectrum of peroxisomal disorders. Neuroradiology. 1991;33:30–7.CrossRefGoogle Scholar
  462. 462.
    van der Knapp MS, Valk J. The reflection of histology in MR imaging of Pelizaeus-Merzbacher disease. AJNR Am J Neuroradiol. 1989;10:99–103.Google Scholar
  463. 463.
    van der Knaap MS, Valk J, de Neeling N, et al. Pattern recognition in magnetic resonance imaging of white matter disorders in children and young adults. Neuroradiology. 1991;33:478–93.PubMedCrossRefGoogle Scholar
  464. 464.
    van der Voorn JP, Pouwels PJ, Hart AA, et al. Childhood white matter disorders: quantitative MR imaging and spectroscopy. Radiology. 2006;241:510–7.PubMedCrossRefGoogle Scholar
  465. 465.
    Van Goethem G, Dermaut B, Löfgren A, et al. Mutation of POLG is associated with progressive external ophthalmoplegia characterized by mtDNA mutations. Nat Genet. 2001;275(28):211–2.Google Scholar
  466. 466.
    van Heijst AFJ, Verrips A, Wevers RA, et al. Treatment and follow-up of children with cerebrotendinous xanthomatosis. Eur J Pediatr. 1998;157:313–6.PubMedCrossRefGoogle Scholar
  467. 467.
    van Heijst AF, Wevers RA, Tangerman A, et al. Chronic diarrhea as a dominating symptom in two children with cerebrotendinous xanthomatosis. Acta Paediatr. 1996;85:932–6.PubMedCrossRefGoogle Scholar
  468. 468.
    Vázquez E, Macaya A, Mayolas N, et al. Neonatal Alexander disease: MR imaging prenatal diagnosis. AJNR Am J Neuroradiol. 2008;29:1973–5.PubMedCrossRefGoogle Scholar
  469. 469.
    Vellodi A, Young EP, Cooper JE, et al. Bone marrow transplantation for mucopolysaccharidoses type I: experience of two British centres. Arch Dis Child. 1997;76:92–9.PubMedPubMedCentralCrossRefGoogle Scholar
  470. 470.
    Verma IM. Gene therapy that works. Science. 2013;341:853–5.PubMedCrossRefGoogle Scholar
  471. 471.
    Verma NP, Hart ZH, Nigro M. Electrophysiologic studies in neonatal adrenoleukodystrophy. Electroencephalogr Clin Neurophysiol. 1985;60:7–15.PubMedCrossRefGoogle Scholar
  472. 472.
    Vilarhino L, Hattori Y, Goto Y-I, et al. Point mutations in mitochondrial tRNA genes: sequence analysis of chronic progressive external ophthalmoplegia (CPEO). J Neurol Sci. 1994;125:50–5.CrossRefGoogle Scholar
  473. 473.
    Vilarinho L, Santorelli FM, Cardoso ML, et al. Mitochondrial DNA analysis in ocular myopathy. Observations in 29 Portuguese patients. Eur Neurol. 1998;39:148–53.PubMedCrossRefGoogle Scholar
  474. 474.
    Vincent I, Bu B, Erickson R. Understanding Niemann-Pick C disease: a fat problem. Curr Opin Neurol. 2003;16:155–61.PubMedCrossRefGoogle Scholar
  475. 475.
    Vingelo EM, Di Fabio R, Salvatore S, et al. Myelinated retinal fibers in autosomal recessive spastic ataxia of Charlevoix-Saguenay. Eur J Neurol. 2011;18:1187–90.CrossRefGoogle Scholar
  476. 476.
    Vivian AJ, Harris CM, Kriss A, et al. Oculomotor signs in infantile Gaucher disease. Neuroophthalmol. 1993;13:151–5.CrossRefGoogle Scholar
  477. 477.
    Vulpe C, Levinson B, Whitney S, et al. Isolation of a candidate gene for Menkes’ syndrome and evidence that it encodes a copper-transporting ATPase. Nat Genet. 1993;3:7–13.PubMedCrossRefGoogle Scholar
  478. 478.
    Vu TH, Sciacco M, Tanji K, et al. Clinical manifestations of mitochondrial DNA depletion. Neurology. 1998;50:1783–90.PubMedCrossRefGoogle Scholar
  479. 479.
    Wallace D. Mitochondrial genetics: a paradigm for aging and degenerative diseases? Science. 1992;256:628–32.PubMedCrossRefGoogle Scholar
  480. 480.
    Walls TJ, Jones RA, Cartlidge N, et al. Alexander’s disease with Rosenthal fibre formation in an adult. J Neurol Neurosurg Psychiatry. 1984;47:399–403.PubMedPubMedCentralCrossRefGoogle Scholar
  481. 481.
    Walshe JM. Wilson disease. In: Vinken PJ, Bruyn GW, Klawans HL, editors. Handbook of clinical neurology, vol. 49. New York: Elsevier; 1986. p. 223–38.Google Scholar
  482. 482.
    Wanders RJ, IJlst L, van Gennip AH, Jakobs C, de Jager JP, Dorland L, van Sprang FJ, Duran M. Long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency: identification of a new inborn error of mitochondrial fatty acid beta-oxidation. J Inherit Metab Dis. 1990;13:311–4.PubMedCrossRefGoogle Scholar
  483. 483.
    Warner TT, Hammans SR. Practical guide to neurogenetics. Philadelphia: Elsevier; 2009. p. 96–7.Google Scholar
  484. 484.
    Watanabe K, Mukawa A, Muto K, et al. Tay-Sachs disease with conspicuous cranial computerized tomographic appearances. Acta Pathol Jpn. 1985;35:1521–32.PubMedGoogle Scholar
  485. 485.
    Wei H, Kemp S, McGuinness MC, et al. Pharmacological induction of peroxisomes in peroxisome biogenesis disorders. Ann Neurol. 2000;47:286–96.PubMedCrossRefGoogle Scholar
  486. 486.
    Weimer JM, Custer AW, Benedict JW, et al. Visual deficits in a mouse model of Batten disease are the result of optic nerve degeneration and loss of dorsal lateral geniculate thalamic neurons. Neurobiol Dis. 2006;22:284–93.PubMedPubMedCentralCrossRefGoogle Scholar
  487. 487.
    Weismann U, Neufeld EF. Scheie and Hurler syndromes: apparent identity of the biochemical defect. Science. 1970;169:72–4.CrossRefGoogle Scholar
  488. 488.
    Welker KM, Patton A. Assessment of normal myelination with magnetic resonance imaging. Semin Neurol. 2012;32:15–28.PubMedCrossRefGoogle Scholar
  489. 489.
    Weller S, Rosewich H, Gärtner J. Cerebral MRI as a valuable diagnostic tool in Zellweger spectrum patients. J Inherit Metab Dis. 2008;31(2):270–80.PubMedCrossRefGoogle Scholar
  490. 490.
    Wetterau JR, Aggerbeck LP, Laplaud PM, et al. Structural properties of the microsomal triglyceride-transfer protein complex. Biochemistry. 1991;30:4406–12.PubMedCrossRefGoogle Scholar
  491. 491.
    Whitley CB, Below KG, Chang PN, et al. Long term outcome of Hurler syndrome following bone marrow transplantation. Am J Med Genet. 1993;46:209–18.PubMedCrossRefGoogle Scholar
  492. 492.
    Whitley CB, Ramsay NK, Kersey JH, et al. Bone marrow transplantation for Hurler syndrome: assessment of metabolic correction. Birth Defects Orig Artic Ser. 1986;22:7–24.PubMedGoogle Scholar
  493. 493.
    Williams DM, Atkin CL. Tissue copper concentrations of patients with Menkes kinky hair disease. Am J Dis Child. 1981;135:375–6.PubMedGoogle Scholar
  494. 494.
    Willemsen MAAP, Cruysberg JRM, Rotteveel JJ, et al. Juvenile macular dystrophy associated with deficient activity of fatty aldehyde dehydrogenase in Sjögren-Larsson syndrome. Am J Ophthalmol. 2000;130:782–9.Google Scholar
  495. 495.
    Willemsen MAAP, Ijst L, Steijlen PM, et al. Clinical, biochemical and molecular genetic characteristics of 19 patients with the Sjögren-Larsson syndrome. Brain. 2001;124:1426–37.PubMedCrossRefGoogle Scholar
  496. 496.
    Willemsen MAAP, Van Der Graaf M, Van Der Knaap MS, et al. MR imaging and proton MR spectroscopic studies in Sjögren-Larsson syndrome: characterization of the leukoencephalopathy. AJNR Am J Neuroradiol. 2004;25:649–57.PubMedGoogle Scholar
  497. 497.
    Wisniewski KE. Neuronal ceroid-lipofuscinosis. GeneReviews. 2006. Accessed 25 Jun 2008.
  498. 498.
    Wolpert S, Elder D, Scott GI. System of ophthalmology. In: Duke-Elder S, editor. Neuro-ophthalmology, vol. 12. London: Henry Kimpton; 1971. p. 222.Google Scholar
  499. 499.
    Wong AM, Héon E. Helicoid peripapillary chorioretinal degeneration in abetalipoproteinemia. Arch Ophthalmol. 1998;116:250–1.PubMedGoogle Scholar
  500. 500.
    Wong L-JC. Mitochondrial syndromes with leukoencephalopathy. Semin Neurol. 2012;32:55–61.PubMedCrossRefGoogle Scholar
  501. 501.
    Wray SH, Cogan DG, Kuwabara T, et al. Adrenoleukodystrophy with disease of the eye and optic nerve. Am J Ophthalmol. 1976;82:480–5.PubMedCrossRefGoogle Scholar
  502. 502.
    Wulff CH, Trojaborg W. Adult metachromatic leukodystrophy: neurophysiologic findings. Neurology. 1985;35:1776–8.PubMedCrossRefGoogle Scholar
  503. 503.
    Yamada K, Toribe Y, Yanagihara K, et al. Diagnostic accuracy of blood and CSF lactate in identifying children with mitochondrial diseases affecting the central nervous system. Brain Dev. 2012;34:92–7.PubMedCrossRefGoogle Scholar
  504. 504.
    Yee RD, Cogan DG, Zee DS. Ophthalmoplegia and dissociated nystagmus in abetalipoproteinemia. Arch Ophthalmol. 1976;94:571–5.PubMedCrossRefGoogle Scholar
  505. 505.
    Yu-Wai-Man P, Pyle A, Griffin H, Santibanez-Korev M, Horvath R, Chinnery PF. Abnormal retinal thickening is a common feature among patients with ARSACS-related phenotypes. Br J Ophthalmol. 2014;98:711–3.PubMedPubMedCentralCrossRefGoogle Scholar
  506. 506.
    Zee DS, Freeman JM, Holtzman NA. Ophthalmoplegia in maple syrup urine disease. J Pediatr. 1974;84:113–5.PubMedCrossRefGoogle Scholar
  507. 507.
    Zupanc ML, Chun RW, Gilbert-Barness EF. Osmiophilic deposits in cytosomes in Hallervorden-Spatz syndrome. Pediatr Neurol. 1990;6:345–52.Google Scholar

Copyright information

© Springer Science + Business Media New York 2016

Authors and Affiliations

  • Michael C. Brodsky
    • 1
  1. 1.Mayo ClinicRochesterUSA

Personalised recommendations